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ABSTRACT 
Enzymes are important drug targets, since they participate in many disease processes and can 
be inhibited by small drug molecules. In our research projects, a group of therapeutically 
important enzymes with polar substrates or products has been investigated by means of 
capillary electrophoresis (CE).  
 
The first enzyme we investigated was ecto-5’-nucleotidase (eN), which can catalyze the 
hydrolysis of the phosphoric acid ester bond of AMP yielding the corresponding nucleoside 
adenosine and inorganic phosphate. Treatment with eN inhibitors may be a promising novel 
strategy for cancer therapy, because eN has been found to be overexpressed on many cancer 
cells, and eN-generated adenosine prevents tumor destruction by inhibiting antitumor immunity. 
We investigated nucleotide mimetics which consisted of a nucleoside scaffold substituted in 
the 5’-position with a dipeptide moiety. The compounds were investigated at rat eN using a 
capillary electrophoresis (CE)-based assay, and potent inhibitors were further investigated at 
human eN. The test results showed that the inhibitory potency of the compounds appeared to 
be pH-dependent: when the buffer pH was decreased, the potency of the compounds increased. 
Since tumor tissues typically show low extracellular pH values, the new inhibitors might act as 
tumor-selective eN inhibitors without affecting physiologically important functions of eN, such 
as the production of adenosine in blood vessels, which shows vasodilatory effects. 
 
The second enzyme that we investigated was cerebroside sulfotransferase (CST), which 
catalyzes the transfer of a sulfate group from the co-substrate 3′-phosphoadenosine-5′-
phosphosulfate (PAPS) to cerebroside yielding cerebroside sulphate and adenosine-3′,5′-
diphosphate (PAP). CST is a promising new therapeutic target for the treatment of 
metachromatic leukodystrophy (MLD), a devastating genetic disease. In the absence of an 
effective therapy, MLD leads to early death of the young patients. In the present study we 
developed a CE-based assay for monitoring the catalytic activity of CST. A low nanomolar 
limit of detection (LOD = 66.6 nM) was achieved for the enzymatic product PAP by using 
dynamic pH junction stacking. Our CE method was sensitive, robust and suitable for CST 
inhibitor screening, Ki value determination, and enzyme kinetic studies. Several reference 
compounds were tested including cerebrosides, psychosine and Congo Red in order to validate 
our method. We investigated analogues of the CST substrate cerebroside with this newly 
developed CE method, in order to study structure-activity relationship (SAR) and to identify 
and develop novel CST inhibitors. A substrate analogue α-galactosylceramide was identified to 
be a novel inhibitor, which will be used as a lead structure for developing more potent 
competitive inhibitors, which are urgently needed for the treatment of MLD. Moreover, SAR 
information for the CST cerebroside binding site would be highly useful especially since a 
crystal structure of the CST cerebroside binding site is not available yet.  
 
A further group of investigated enzymes were capsule biosynthesis enzymes from 
Staphylococcus aureus. We characterized the enzymes CapD and CapE of the Staphylococcus 
aureus serotype 5 biosynthesis cluster, which catalyze the first steps in the synthesis of the 
soluble capsule precursors UDP-D-FucNAc and UDP-L-FucNAc, respectively. A capillary CE-
based method applying micellar electrokinetic chromatography (MEKC) was developed for the 
functional characterization of the enzymes using dynamic coating of the capillary with 
polybrene at pH 12.4. The limits of detection for the CapD and CapE products UDP-2-
acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose and UDP-2-acetamido-2,6-dideoxy-β-L-
arabino-hex-4-ulose, respectively, were below 1 µM. Using this new, robust and sensitive 
method we performed kinetic studies for CapD and CapE, and screened a compound library in 
search for enzyme inhibitors. Several active compounds were identified and characterized. Our 
studies contribute to a profound understanding of the capsule biosynthesis in pathogenic 
bacteria. This approach may lead to the identification of novel anti-virulence and antibiotic 
drugs. 
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1 Introduction  
1.1     Enzymes  
1.1.1 Enzymes as drug targets 
Enzymes are attractive drug targets for pharmaceutical industry. Therefore nearly half of the 
drugs in clinical use today are enzyme inhibitors.1 There are two main reasons for enzymes to be 
attractive targets for pharmacological research: one is the essential participation of enzymes in 
many disease processes, another reason is that enzymes can be inhibited by small drug 
molecules.1 Enzyme catalysis is necessary for life. A classification of enzymes according to their 
catalytic ability is shown in Table 1.1.2 
 
Table 1.1. Classification of enzymes 
Classification Related enzymes used in the current research project 
Oxidoreductases 
 
Oxidoreductases are 
enzymes that 
catalyze oxidations 
and reductions 
 
 
- 
 
Transferases 
 
Transferases are 
enzymes that transfer 
a group from one 
molecule to another 
 
Cerebroside sulfotransferase (CST) can catalyze the transfer of a sulfate 
group from PAPS to cerebrosides 
 
Hydrolases 
 
Hydrolases are 
enzymes that 
hydrolyze 
compounds 
containing an ester 
or amide group 
 
Ecto-5’-nucleotidase (eN, CD73) can catalyze the hydrolysis of the 
phosphoric ester bond of AMP to the corresponding nucleoside 
adenosine and inorganic phosphate 
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Lyases 
 
Lyases are enzymes 
that catalyze the 
cleavage of C-C, C-
O, C-N, and other 
bonds by other 
means than by 
hydrolysis or 
oxidation 
 
CapD can catalyze UDP-D-GlcNAc to UDP-2-acetamido-2,6-dideoxy-α-
D-xylo-hex-4-ulose  
 
 
Isomerases 
 
Isomerases are 
enzymes that 
catalyze the 
interconversion of all 
types of isomers 
 
- 
Ligases (synthases) 
 
Ligases are enzymes 
that catalyze the 
formation of a bond 
between two 
substrate molecules 
  
 
- 
 
The arrangement in the enzymes’ active site must change (including spatial orientation, bond 
strength and bond angle), in order to catalyze the transformation of substrate into product. To 
achieve this goal, the overall conformation of the enzyme must adjust, which will cause changes 
in both active site and potential allosteric sites. Some features of the active site structure that 
relate to enzyme catalysis and ligand interactions are described below:1 
1. The active site of an enzyme is small compared to the whole enzyme.  
2. The amino acids and cofactors in the active site are held in precise arrangement with respect 
to the substrate.  
3. Usually the initial interactions between the enzyme and the substrate are noncovalent. For 
example, H-bond, electrostatic, hydrophobic, and van der Waals (VDW) interactions are 
observed. 
4. The active site of enzymes usually is located in the clefts of the protein, which can exclude 
bulk solvent. The substrate molecule is desolvated upon binding, and it is shielded from bulk 
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solvent in the enzymes’ active site, where the solvation is replaced by specific interactions 
within the protein.  
5. The specificity of substrate utilization depends on the arrangement of atoms in the enzymes’ 
active site.  
The main features of enzyme’s allosteric sites were initially presented by Monod, Wyman, and 
Changeux (known as MWC theory), which is shown in Figure 1.1:3  
1. The proteins may have a quaternary structure with more than one identical subunits (e.g. 
human ecto-5’-nucleotidase exists as a dimer 4 ).  
2. A relaxed state and a tensed state both exist, and the transitions between these two 
conformations are reversible.3 For example, the tensed and relaxed states coexist in ecto-5’-
nucleotidase crystals.4 Ligands would facilitate the transitions between two confirmations: 
activators would let the enzyme transit preferably to the relaxed state, while allosteric inhibitors 
would let the enzyme transit preferably to the tensed state. 
 
 
Figure 1.1. MWC model of allosteric sites and allosteric transitions.3 Three class of molecules 
can bind to the enzyme: A (activator), I (inhibitor), and S (substrate). Transition between two 
states: relaxed state, tensed state, and the hypothetical monomer are shown. 
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1.1.2 Enzyme kinetic mechanisms 
 
A simple enzyme-catalyzed reaction, which converts only one substrate into product can be 
described as below:1 
 
In a rapid equilibrium, an initial loose association complex is formed between enzyme E and 
substrate S. Subsequently, the enzyme shifts to its active form and then converts substrate S into 
product P. Then the enzyme changes back to its inactive state, and meanwhile the product P 
dissociates from the enzyme. This process is time-dependent, and the time-dependent changes of 
the reactants of an enzyme-catalyzed reaction can be divided into three phases (Figure 1.2):5 
1. Pre-steady-state phase: in the very beginning of this process, the complex ES is formed, 
meanwhile the free enzyme E decreases. The turnover rate v is low in this phase.  
2. Steady-state phase: in this phase the turnover rate v reaches its maximum. The concentration 
of complex ES remains the same.  
3. Substrate depletion: since more and more substrate S is converted to product P, the depletion 
of the substrate S will cause the decay of complex ES, which decreases the turnover rate v.  
The mathematical description of enzyme kinetics is shown in equation 1, where the term Vmax 
refers to the maximum velocity obtained at infinite substrate concentration.1 Vmax is 
mathematically equivalent to the product of kcat and the enzyme concentration (equation 2).1 The 
steady state enzyme velocity as a saturable function of substrate concentration could be described 
as equation 3, which is called the Michaelis-Menten equation, and is only valid in the steady-
state.1 
 
 SK
SVv
s 
 max          (1) 
 EkV catmax         (2) 
 
 SK
SVv
m 
 max          (3) 
E + S ES E + P 
kcat 
Ks
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Figure 1.2. Time-related changes of the reactants in an enzyme-catalyzed reaction5. Where E 
stands for the enzyme, S stands for the substrate, ES stands for the enzyme-substrate complex. 
 
Briefly, the relationship between steady state kinetic constants kcat, Km , and kcat/Km and enzyme 
reaction pathway could be describe as below:1 
 Km relates to ES dissociation:      ES → E + S 
 1/Km relates to ES formation:      E + S → ES 
 kcat relates to transition from ES to product:      ES → E + P 
 kcat/Km relates to transition from the reactant state to product:      E + S →  E + P 
 
1.1.3 Enzyme inhibitors 
 
Enzyme inhibition is defined as the negative effect on enzyme activity by inhibitors specifically 
binding to defined catalytic or regulatory centers. Some inhibitors bind so strongly to the enzyme 
that they cannot be detached, but most inhibitors bind reversibly and can be released or displaced 
from the enzyme. The former is irreversible inhibition, and the latter is reversible inhibition. 
Most drugs bind to their enzyme target through reversible interaction, as shown in Figure 1.3. 
There are three major forms of reversible enzyme inhibitor reactions.1 Competitive inhibitors 
only bind to the same binding site as the substrate, uncompetitive inhibitors only bind to the 
enzyme’s allosteric site, and noncompetitive inhibitors bind to both, substrate binding site and 
enzyme allosteric site. The ligand binding event can stabilize a particular microstate of the 
enzyme. This can shift the distribution of the enzyme states, because there is an energy barrier to 
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interconvert from one microstate to another microstate. The highest affinity inhibitor binding 
microstate can occur anywhere along the reaction pathway of the enzyme.1 
 
 
Figure 1.3. Three major forms of reversible inhibitor interactions with enzymes:1 (a) competitive 
inhibition; (b) noncompetitive inhibition; (c) uncompetitive inhibition; (d) enzyme turnover 
equilibrium. E stands for enzyme, S stands for substrate, I stands for inhibitor, EI stands for 
enzyme-inhibitor complex, ES stands for enzyme-substrate complex, and ESI stands for enzyme-
inhibitor-substrate complex. 
 
 
 
There are several ways to determine the inhibition type of reversible inhibitors. One popular way 
is to use the Lineweaver-Burk plot. A summary of the Lineweaver-Burk equation and plot for 
non-competitive inhibition, competitive inhibition and uncompetitive inhibition, and effects of 
inhibitions with different modalities are described in Table 1.2.1 
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Table 1.2. Lineweaver-Burk equation and plot for non-competitive inhibition, competitive 
inhibition and uncompetitive inhibition, and effects of inhibition with different modalities 1 
 
 
Inhibition 
type 
Effects of inhibitions with 
different modalities 
 
Lineweaver-Burk equation and plot 
Km Vmax 
 
N
on
-C
om
pe
tit
iv
e 
 
α > 1 
Increases 
curvilinearly 
with increasing 
[I] 
Decreases 
curvilinearly 
with increasing 
[I] 
   
 AV
K
IK
V
K
I
v
i
m
i



 



11
1 
 
 
α = 1 
 
No effect 
Decreases 
curvilinearly 
with increasing 
[I] 
 
α < 1 
Decreases 
curvilinearly 
with increasing 
[I] 
Decreases 
curvilinearly 
with increasing 
[I] 
 
C
om
pe
tit
iv
e 
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linearly with 
increasing [I] 
 
 
 
 
 
 
No effect 
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There are two important parameters for describing inhibition potency: IC50 value and Ki value. 
The IC50 value is dependent on substrate concentration, but it is easier to be evaluated than the Ki 
value. The Ki value is more comparable to inhibition potency than the IC50 value, because it is 
independent from the substrate amount, but the determination of the Ki value is more 
complicated than that of the IC50 value. Therefore we usually determine the IC50 value first, in 
order to have an overview of the screening hits, and then we carry out Ki value determination for 
the most potent compounds to make the inhibition potency comparable between different test 
methods or between different laboratories. As shown in equation 4, the IC50 value is the 
concentration of inhibitor that results in inhibiting half of the maximal enzyme activity (Top - 
Bottom): 
 
50log101
)(
ICx
BottomTopBottomY 
       (4) 
 
There are two popular ways for Ki value determination: by using the mixed-model inhibition 
equation6 (it is also implemented in the software package Prism5), or by using the Dixon plot.7,8  
 
1.1.4 Inhibitor screening, Ki value determination 
 
Inhibitor screening, and Ki value determination are the essential investigations of therapeutically 
important enzymes. The goal of inhibitor screening is to identify new enzyme inhibitors from 
compound libraries. Usually we use % Inhibition at a certain inhibitor concentration [I] to 
present the screening result, and the equation of % Inhibition is shown in equation 5, where vi 
and v0 are the reaction velocity in the presence and absence of inhibitor at concentration [I], 
respectively, and Sb is the background signal. 
)1(100%
0 b
bi
Sv
SvInhibition 
       (5) 
The goal of inhibitor Ki value determination is to further characterize the property of potent 
inhibitors. Inhibition type determination is required before inhibitor Ki value calculation, and 
enzyme kinetic studies with Michaelis-Menten curves are needed. Moreover, measuring initial 
velocity is an important experimental aspect for enzyme inhibitor investigation. Since only 
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during the initial velocity phase (up to about 10-20% substrate depletion) can the % Inhibition be 
relatively constant and close to the true value,1 the substrate conversion rate in all enzyme 
inhibition assays should be strictly kept below 20%. The last but not least important point is that, 
a proper enzyme amount within the linear portion of enzyme titration on the observed reaction 
velocity is needed, in order to avoid an additional influence of the enzyme concentration factor.1 
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1.2 Capillary electrophoresis 
1.2.1 Introduction of capillary electrophoresis 
Capillary electrophoresis (CE) is a separation method, which is based on differences of analyte 
velocities in an electric field. The CE separation is performed in narrow-bore capillaries. 
Separation is an important method in analytical chemistry. A separation process means 
transforming a mixture of analytes into several pure distinct analytes. 
 
 
        
 
Figure 1.4. CE working process. A. Presentation of the CE system. B. Separation of analytes 
within the capillary according to time. 
 
Figure 1.4 shows the CE working process. At time t0, a mixture which contains three analytes is 
injected into the capillary. The three analytes have different velocities, therefore some of them 
move faster inside the capillary, while some of them move slower. After time t3 the separation is 
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completed. Since these solutes have certain spectra, an optical detector is used for the signal 
detection. 
The velocity (v) of an ion in an electric field can be described by equation 6, where µe is mobility, 
and E is the applied electric field:9 
v = µe E      (6) 
When an ion moves in an electric field, there are two forces applied on it. One is the electric 
force FE (equation 7, where q is ion charge); another one is frictional drag through the medium Ff 
(equation 8, where ƞ is solution viscosity, r is ion radius). After a short time, the two forces will 
create an equilibrium: FE = Ff , leading to equation 9:9 
FE = q E        (7) 
Ff = 6πηrv = 6πηrµe E        (8) 
µe = 
r6
q
      (9) 
Additionally, electro-osmotic flow (EOF) is a fundamental constituent of CE separation, which is 
the bulk flow of liquid in the capillary. It is a consequence of the surface charge on the silica 
capillary inner wall. The EOF is controlled by the numerous silanol groups (SiOH) that can exist 
in anionic form (SiO-). When the silanol groups are deprotonated in the solution (at pH > 4), 
cations from the running buffer will build up near the surface to maintain a charge balance 
(Figure 1.5). When the voltage is applied across the capillary, cations near the capillary surface 
will move towards the cathode and drag the bulk solution together with them. The magnitude of 
the EOF mobility is described in equation 10, where ε is the dielectric constant, and ζ is the zeta 
potential:9 
μos = (ε ζ / η)      (10) 
So the mobility of an ion that moves inside the capillary can be described as in equation 11:9 
μ = μe + μos      (11) 
Usually the magnitude of μos is much bigger than that of μe, therefore all the solutes will move 
towards the cathode. EOF mobility (μos) can be adjusted through many ways; for example, by 
increasing buffer concentration one can decrease the zeta potential and EOF mobility; lowering 
of the electric field can decrease the EOF mobility; by using coated capillary walls one can 
increase, decrease or reverse the surface charge and the EOF mobility.  
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Figure 1.5. EOF in fused-silica capillary 
 
Resolution is an important evaluation parameter for CE separation quality. It is defined in 
equation 10, where w is baseline peak width (in time), ϭ is the temporal standard deviation, t is 
migration time, w is peak width, and subscripts 1 and 2 refer to the two solutes:9 
R = 
21
12
ww
)t-

t(2  = 

4
tt 12       (12) 
From equation 12 we can deduce that a better resolution (R) will be achieved when the peak 
width (w) is smaller. In other words, a good resolution needs sharp analyte peaks. In order to 
make analyte peaks sharp, usually the injection plug length should be less than 1 mm, and a 
stacking approach is required when a large volume of analyte is injected. Figure 1.6 shows: as 
the injection amount is increased, the peak size is increased, and resolution R is decreased, and 
finally peak distortion occurs (at -10 kV for 60 seconds). 
 
Figure 1.6. An example to show how the injection influences resolution. Separation of PAP and 
PAPS in a dynamically coated capillary. Separation buffers: phosphate 75 mM, with 0.002% 
polybrene, pH 8 (adjusted by phosphoric acid), separation voltage -25 kV, capillary temperature 
15°C, and capillary length (50 cm * 75 µM). A: injection -6 kV for 10 seconds, R=1.6; B: 
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injection -6 kV for 30 seconds, R=1.05; C: injection -10 kV for 30 seconds, R=0.82; D: injection 
-6 kV for 60 seconds, R=0.67; E: injection -10 kV for 60 seconds, R=0.60. 
There are two kinds of injection methods: hydrodynamic injection and electrokinetic injection. 
Electrokinetic injection is dependent on the EOF, sample concentration, and sample mobility in 
the electric field. The quantity injected, Q (g or moles), can be calculated by equation 13, where r 
is the capillary radius, c0 is the analyte concentration, τ is the injection duration:9  
 
Qin = π r2c0 (μe + μos) Eτ      (13) 
 
One important feature of electrokinetic injection is the injection difference between different ions, 
which is caused by different mobility of different ions in the same electric field. The 
hydrodynamic injection volume V can be calculated by equation 14, where P  is injection 
pressure difference across the capillary:9 
V = 
 )P(
L8
r 4       (14) 
Usually P  is around 0.5 psi, τ is around 1-5 s. Equation 14 shows that the hydrodynamic 
injection volume will decrease when the total length of the capillary increases. There is no 
injection selection between different ions within the same sample solution, but both, analytes and 
background substances, will be injected into the capillary by using hydrodynamic injection. 
There are three kinds of detectors for CE: ultraviolet (UV) detector, diode array detector (DAD) 
detector, and laser-induced fluorescence (LIF) detector. The UV detector and DAD detector are 
suitable for compounds that absorb light in the ultraviolet (UV) range, 200-400 nm. Absorption 
of light occurs when electrons of irradiated absorbing molecules are promoted to a higher energy 
level, because the frequency of the electronic oscillation in the molecule coincides with the 
frequency of the irradiating light. The wavelength corresponding to this frequency (λmax) is that 
at which the compound absorbs most light. It is determined by the structure of the absorbing 
molecule. Instruments designed to measure absorbance invariably make their measurements by 
determining the amount of light that is not absorbed, that is, the light which is transmitted by the 
solution. Naturally, the light transmitted by a solution of a chromophore decreases as the 
concentration of the chromophore increases. Any instrument that measures absorbance must 
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make a comparison of I0 (the light transmitted by a solution not containing the chromophore), 
with I (the light transmitted by a solution that does contain the chromophore), and the absorbance 
can be calculated with the Lambert-Beer equation (equation 15):9 
)/(log 010 IIA        (15) 
The UV detector (fixed wavelength detector) utilizes lamps that emit light at discrete wave 
lengths. The DAD detector (variable wavelength detector) uses light sources that give a 
continuous emission spectrum in a large range. A continuously adjustable monochromator is 
used for wavelength selection. The LIF detector (fluorescence detector) is suitable for fluorescent 
compounds. The phenomenon of fluorescence is, like that of absorption, the result of an 
electronic transition which converts the absorbing molecule to an excited state. The difference 
between fluorescent and non-fluorescent compounds is determined by what happens when the 
excited state returns to the ground state. The non-fluorescent molecules lose their energy as heat, 
while the fluorescent molecules emit part of the energy as light. During the period between 
absorption and emission, the molecule loses some of its energy by vibrational relaxation so that 
the emitted light is of lower energy and consequently higher wavelength than the exciting light. 
The LIF detector possesses high sensitivity, because the intensity of emitted light is directly 
proportional to the power of the exciting radiation. This method can be used to detect compounds 
that have intrinsic fluorescence or can be derivatized by reacting with a fluorescent compound, 
e.g. fluorescamine or dansyl chloride.  
Compared to other separation methods (such as high performance liquid chromatography 
(HPLC), or thin-layer chromatography), CE has several advantages:  
1. CE is applicable to a wider selection of analytes (small molecules and proteins). 
2. CE requires minute amounts of sample. 
3. CE consumes limited quantities of reagents (organic solvents are expensive to purchase, to 
store and to dispose) 
To establish a good CE method, we aim to achieve good separation, good detection (low 
concentration of analyte), good reproducibility, and minimum amount of analytical steps. It is 
easier to detect analytes in pure standard solutions than in biological matrices, because biological 
samples contain high salt and high protein amounts. For high salt-containing samples, one can 
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use high concentration separation buffers. There are three ways to prepare high protein-
containing samples before injection: 
1. We can perform deproteinization before the CE separation with acetonitrile. When the 
protein size is smaller than 5000 Da, acetonitrile (2 volumes acetonitrile: 1 volume protein 
serum) is a good means to remove the protein, while acetonitrile can also provide sample 
stacking.  
2. Micellar electrokinetic chromatography (MEKC) is a way to prevent protein adsorption to 
the capillary wall, because the MEKC surfactants solubilize proteins. 
3. For analysis of small analytes, simple deproteinization can be performed by taking the 
analyte from the supernatant. 
There is a group of important parameters for bioanalytical method validation according to the 
guidelines published by the International Conference on Harmonisation (ICH) of Technical 
Requirements for Registration of Pharmaceuticals for Human Use, and the US Food and Drug 
Administration (FDA), respectively,10,11 including limitation of quantification (LOQ), limitation 
of detection (LOD), precision and accuracy. LOQ presents the lowest concentration of an analyte 
in a sample that can be quantitatively determined with a certain method, and LOD presents the 
lowest concentration that the bioanalytical procedure can reliably differentiate from background 
noise. LOQ and LOD can be obtained from equation 14 and equation 15, respectively. 
 
LOQ = (Sy.x/slope)*10      (14) 
LOD = (Sy.x/slope)*3.3     (15) 
Where Sy.x and slope can be obtained from linear regression of the calibration curve. 
 
Precision is the closeness of a series of measurements obtained from multiple sampling of the 
same homogenous sample under the described conditions, which can be presented with relative 
standard deviation (RSD) in an acceptable range of 20%.10,11 Accuracy is the degree of closeness 
of the determined value to the true value, which has an acceptable range of 80-120%.10,11 
1.2.2 Stacking methods for capillary electrophoresis  
Micellar electrokinetic chromatography (MEKC) is a popular technology for increasing detection 
sensitivity of CE, which introduces micelles or surfactants into the CE running buffer.12 The 
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addition of cationic surfactants to the running buffer causes a reversal of the EOF, because the 
capillary is positively charged by adsorption of cationic surfactants.13,14  
As shown in Figure 1.7, by using polybrene dynamic coating, both EOF and negatively charged 
analytes move towards the positive electrode. The more the analytes are negatively charged, the 
faster they migrate towards the detection window. Moreover, by electrokinetic injection, more 
negatively charged analytes can be selectively injected into the capillary.  
Another simple CE sample pre-concentration method is field amplified sample stacking (FASS), 
which means to use a low concentration of sample matrix and a high concentration separation 
buffer.12 The mechanism can be described as follows: sample ions have an enhanced 
electrophoretic mobility in a lower conductivity environment. When voltage is applied to the 
capillary, ions in the sample plug accelerate towards the adjacent separation buffer zone. On the 
boundary, the ions slow down because of the higher conductivity environment, so that the 
sample components are stacked within a smaller zone. 
 
 
Figure 1.7. Differences between normal fused-silica and polybrene coated fused-silica capillary 
 
 
 
21 
A further CE sample stacking method, which was applied in our research project, is the dynamic 
pH junction method, which means to fill in buffers of different pH values into the capillary in 
order to achieve stacking effects on the boundary of the different buffers.12 The detailed 
mechanism of the dynamic pH junction stacking method is described in Chapter 4. 
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2 Investigation of ecto-5’-nucleotidase - a novel anti-cancer drug 
target 
2.1 Introduction 
Ecto-5’-nucleotidase (eN), a Zn2+-binding glycosylphosphatidylinositol-(GPI)-linked membrane-
bound hydrolytic enzyme, plays a crucial role in switching on adenosine signaling via the P1 
receptors (A1, A2A, A2B, A3).15,16 Since P1 receptors have a very broad tissue distribution and are 
involved in multiple physiological functions, eN became a therapeutically interesting target for 
the treatment of inflammation, chronic pain, hepatic fibrosis, cancer and neurological 
disorders.17–27 More interestingly, eN has been found to be overexpressed on many cancer cells, 
which enhances tumor growth and metastasis,20,28–30 and deletion of eN on tumor cells 
significantly improved anti-tumor T cell immunity. Moreover, both, local and systemic 
production of adenosine by eN, might modulate anti-tumor responses in vivo (see Figure 2.8).28 
Therefore, treatment with eN inhibitors might be a promising novel strategy for cancer therapy.  
eN belongs to the ecto-nucleotidase family, which consists of four main groups or families of 
ecto-nucleotidases: the E-NTPDase family (ecto-nucleoside triphosphate diphosphohydrolase 
family), the E-NPP family (ecto-nucleotide pyrophosphatase/phosphodiesterase family), ecto-5’-
nucleotidase (eN), and alkaline phosphatases (AP).31,32 Extracellular nucleotides, which act as 
signaling molecules, can be inactivated by hydrolysis via ecto-nucleotidases (Figure 2.1). eN  
hydrolyzes extracellular nucleoside monophosphate (AMP) to adenosine.33 In mammals, the 
cytosolic 5’-nucleotidase and the ecto-5’-nucleotidase (eN) are structurally unrelated.34 
Determination of the primary structures of eN (from human placenta, rat liver and the electric ray 
fish) showed that in all three cases the mature enzymes consist of 548 amino acids with a 
molecular mass of about 61 kDa, and a metal content of two zinc ions per dimer was 
determined.34,35 The primary structures of eN which were determined from rat liver and human 
placenta display nearly 90% amino acid identity.36 The crystal structures of eN showed that the 
mammalian eN forms dimers, and the C-terminal domain contains the dimerization interface 
(Figure 2.2).4,37,38 
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Figure 2.1. Overview of extracellular nucleotide metabolism pathway.15 (a) Degradation of 
extracellular nucleotides and purinergic receptor activation. (b) Ecto-anabolism of nucleotides. 
 
 
 
Figure 2.2. Crystal structure of human eN in an open conformation, and a closed conformation.4 
The N- and C-terminal domains of one subunit of the dimer are shown in blue and green, 
respectively. The N- and C-terminal domains of the adjacent subunit are shown in orange and 
yellow, respectively. Ligands (adenosine and AOPCP in the open and closed forms respectively) 
are shown as red sticks while the metal ions are shown as gray spheres. 
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It has been well known that nucleoside analogues are cornerstones of treatment for patients with 
cancer, and have been in clinical use for almost 50 years.39 Novel nucleoside analogues still 
possess great potential, due to their increased selectivity and reduced side-effects in comparison 
with previously developed compounds.  
We investigated nucleotide mimetics which consisted of a nucleoside scaffold substituted in the 
5’-position with a dipeptide moiety. The compounds were investigated at rat eN using a capillary 
electrophoresis-based assay. Potent inhibitors were further investigated at human eN.40 The test 
results showed that the inhibitory potency of the compounds appeared to be pH-dependent: when 
the buffer pH was decreased, the potency of the compounds increased. Since low extracellular 
pH values are a hallmark of cancer (the extracellular pH value in normal tissue is around 7.5, and 
in many tumor tissue is more acidic and can be as low as 5.8),41–45 the new inhibitors might act 
as tumor-selective eN inhibitors without affecting physiologically important functions of eN, 
such as the production of adenosine in blood vessels, which shows vasodilatory effects.46 
 
2.2 Method development and validation 
2.2.1 Optimization and validation of capillary electrophoresis method  
 
A sensitive method for eN testing has been previously published,40 and we further optimized this 
method by introducing an internal standard (I.S.) into the sample preparation step. An internal 
standard was not used in the published method, however, by using I.S., both, systematic errors 
and random errors can be avoided.47 We tried different internal standards with various 
concentrations. Uridine 6.25 µM has been found to be most suitable. A typical electropherogram 
of the eN reaction is shown in Figure 2.3. The limit of quantification (LOQ) was improved from 
4.07 µM to 2.70 µM, while the accuracy and precision values were within a well acceptable 
range for the measurement of low concentrations of analytes.10,11  
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Table 2.1. Quantification of eN reaction product with different I.S.: method validation 
 
Parameters I.S. UMP, 25 µM I.S. Uridine, 6.25 µM 
 
Regression 
equation 
(n=6) 
 
y = 4.974 x - 4.882 
0 20 40 60 80 100
0
100
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500
concentration of adenosine (µM)
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rr
.a
re
a 
di
vi
de
d 
by
 I.
S
.
 
y = 12.16 x - 1.654 
0 10 20 30 40 50
0
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400
600
concentration of adenosine (µM)
co
rr
.a
re
a 
di
vi
de
d 
by
 I.
S
.
R2 0.9988 0.9996 
LOD (µM) 3.14 0.89 
LOQ (µM) 9.51 2.70 
Calibration 
range (µM) 
 
5 - 80 
 
  5 - 40 
 Concentration 
(µM) 
Accuracy 
(n=6, % 
recovery) 
Accuracy 
acceptable 
rangea 
Precision 
(n=6, RSDb 
%) 
Precision 
acceptable 
rangea 
 
I.S
. U
M
P 
pr
od
uc
t 
 
40 109.6 80-120% 4.1 20% 
20 99.3 80-120% 5.9 20% 
10 95.5 80-120% 4.5 20% 
5 101.4 80-120% 2.1 20% 
 
I.S
. U
rid
in
e 
pr
od
uc
t 
 
40 106.7 80-120% 4.3 20% 
20 101.7 80-120% 2.7 20% 
10 101.5 80-120% 1.3 20% 
5 100.6 80-120% 0.8 20% 
 
a According to guidelines of the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 10   
 
b Relative standard deviation 
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Figure 2.3. Representative electropherogram of eN. Borax buffer (40 mM), pH 9.1, 
hydrodynamic injection 0.5 psi, 5 sec), λmax = 260 nm, separation voltage = 20 kV. Uncoated 
fused-silica capillaries of 40 cm total length (30 cm effective length) × 75.5 µm (inner diameter) 
× 363.7 µm (outer diameter). Peaks: 1, buffer; 2, adenosine; 3, I.S. uridine. 
 
2.3 Results 
2.3.1 Kinetic characterization of ecto-5’-nucleotidase-catalyzed reactions 
 
Reported Km values for the eN substrate AMP range between 1 and 50 µM.15,48–51 We used 
reaction buffers with different pH values to determine the Km value of AMP. As shown in Figure 
2.4, eN (rat enzymes) displayed a Km value of 50.4 ± 10.2 µM and a Vmax value of 0.281 ± 0.013 
µmol/min/mg in pH 4.9 buffer; a Km value of 45.9 ± 5.28 µM and a Vmax value of 0.738 ± 0.096 
µmol/min/mg was obtained in pH 5.6 buffer; and a Km value of 45.2 ± 3.2 µM and a Vmax value 
of 1.31 ± 0.10 µmol/min/mg was determined in pH 7.4 buffer. The three enzyme kinetic curves 
at different pH values were determined at the same time with the same enzyme aliquot. 
Therefore data are well comparable. The stability of the enzyme was tested, and the result 
showed that the enzyme was stable during the incubation time. The buffer pH stability during the 
enzyme reaction was tested, and the result showed that the buffer kept the same pH range during 
the enzymatic reaction. The enzyme is more active at higher pH value, indicated by decrease in 
the Vmax values with decreasing pH value, while the Km values stayed around 45 µM. 
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Figure 2.4. Enzyme kinetics of eN. Michaelis-Menten plot for eN in reaction buffers with 
different pH values, each curve was carried out in three independent assays. At pH 4.9, Km 50.4 
± 10.2 µM, Vmax 0.281 ± 0.013 µmol/min/mg; at pH 5.6, Km 45.9 ± 5.28 µM, Vmax 0.738 ± 0.096 
µmol/min/mg; at pH 7.4, Km 45.2 ± 3.2 µM, Vmax 1.31 ± 0.10 µmol/min/mg. 
 
2.3.2 Inhibitors of ecto-5’-nucleotidase 
 
We tested a series of novel nucleotide mimetics which consisted of a nucleoside scaffold 
substituted in the 5’-position with a dipeptide moiety (Table 2.2). The compounds were 
investigated at rat eN, and several compounds have been found out to be pH-dependent inhibitors: 
when the buffer pH values decreased, the potency of the compounds increased. The most potent 
pH-selective compound AMB552.3a was further investigated at human eN, and its pH-
dependent inhibition manner was found to be retained at human eN. Furthermore, the inhibition 
mechanism for ATP, AOPCP and AMB552.3a in pH 5.6 buffer was investigated (Figure 2.5). 
AMB552.3a was found to act as a non-competitive inhibitor, while ATP and AOPCP appeared to 
be competitive inhibitors. 
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Table 2.2. Test result of pH-dependent inhibitors and reference compounds 
 
No. Code 
name 
Structure rat eN 
IC50  SEM (µM) 
 (or % inhib. at 100 
µM) 
at pH 5.6 
rat eN 
IC50  SEM (µM) 
 (or % inhib. at 100 
µM) 
at pH 7.4 
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Figure 2.5. Determination of enzyme inhibition mechanism of AMB552.3a and reference 
compounds at buffer pH 5.6. (A) eN inhibition by AMB552.3a is non-competitive (AMB552.3a 
concentrations for determination were 2 µM, 5 µM, 10 µM and 15 µM); (B) eN inhibition by 
AOPCP is competitive (AOPCP concentrations for determination were 0 µM, 0.1 µM and 0.5 
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µM); (C) eN inhibition by ATP is competitive (ATP concentrations for determination were 0 µM, 
50 µM and 75 µM). 
 
 
Additionally, a series of polyoxometalates (POMs), which contain early transitional metal ions 
such as tungsten (W), molybdenum (Mo), niobium (Nb), antimony (Sb) or vanadium (V) 
surrounded by oxygen atoms, has been tested at rat eN (see Table 2.3). Polyoxometalates (POMs) 
are inorganic cluster metal complexes that have been shown to possess a variety of biological 
activities such as antibacterial, anticancer, antidiabetic, and antiviral effects.52–54 Several 
inhibitors of eN have been identified (Table 2.3), and the inhibition mechanisms were 
investigated (Figure 2.6). These inhibitors are KB1, KB2 and KB4, which are all non-
competitive, with IC50 values 11.4 ± 1.8, 52.3 ± 27.2, and 4.57 ± 1.28 µM, respectively. The 
aqueous solubility of KB4 and KB1 was good, whereas the solubility of KB2 was poor.  
 
Table 2.3. Test result of POMs 
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(Ki  SEM µM) 
 
Inhibition curves 
 
 
 
KB1 
 
 
 
 [(Re6S8)(OH)6]4- 
 
 
 
 
 
11.4 ± 1.8 
(Ki = 12.9 ± 5.5 
α Ki = 12.6 ± 7.0)  
 
10-7 10-6 10-5 10-4 10-3
0
10
20
30
40
50
60
70
80
90
100
110
[KB1], M
R
es
id
ua
l a
ct
iv
ity
 o
fe
N
 (%
)
 
 
 
 
KB2 
 
  
 
[(Re6Se8)(OH)6]4- 
 
 
 
 
52.3 ± 27.2 
(Ki = 25.6 ± 13.7 
α Ki = 19.4 ± 1.6)  
 
 
10-7 10-6 10-5 10-4 10-3 10-2
0
10
20
30
40
50
60
70
80
90
100
110
[KB2], M
R
es
id
ua
l a
ct
iv
ity
 o
fe
N
 (%
)
 
 
 
34 
 
 
 
 
KB4 
 
  
 
 
[(Re6S8)(HCOO)6]5- 
 
 
 
 
 
4.57 ± 1.28 
 (Ki = 2.89 ± 0.32 
α Ki = 2.54 ± 0.24)  
 
 
10-8 10-7 10-6 10-5 10-4 10-3
0
10
20
30
40
50
60
70
80
90
100
110
[KB4], M
R
es
id
ua
l a
ct
iv
ity
 o
fe
N
 (%
)
 
 
 
 
-0.10 -0.05 0.05 0.10
-1
1
2
3
4
KB1 _0 µM
KB1 _2 µM
KB1 _10 µM
             1/[A]
1/
V
-0.10 -0.05 0.05 0.10
-10
-5
5
10
KB2 _0 µM
KB2 _20 µM
KB2 _50 µM
               1/[A]
   
   
   
   
   
   
   
 1
/V
-0.10 -0.05 0.05 0.10
-2
2
4
KB4 _0 µM
KB4 _1 µM
KB4 _4 µM
             1/[A]
   
   
   
   
   
  1
/V
A
B
C
 
Figure 2.6. Determination of enzyme inhibition mechanism. (A) eN inhibition by KB1 is non-
competitive (KB1 concentrations for determination were 0 µM, 2 µM and 10 µM); (B) eN 
inhibition by KB2 is non-competitive (KB2 concentrations for determination were 0 µM, 20 µM 
and 50 µM); (C) eN inhibition by KB4 is non-competitive (KB4 concentrations for 
determination were 0 µM, 1 µM and 4 µM). 
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2.3.3 Activators of ecto-5’-nucleotidase 
Previous reports showed that eN can be activated by thyroid hormones and protein kinase C.55–57 
In the present study we have found two new activators of rat eN at pH 7.4 (Figure 2.7), 
NaCP8W12 and AMB552.3a activated eN with EC50 values of 11.4 ± 1.3 µM, and 3.05 ± 0.57 
µM, respectively. 
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Figure 2.7. Activators of eN at pH 7.4 in HEPES buffer. The concentration of eN substrate AMP 
was 500 µM (Km 45 µM) (A) Activation of eN by NaCP8W12 was up to 400%, the EC50 value 
was 11.4 ± 1.3 µM (B) Activation of eN by AMB552.3 was up to 200%, the EC50 value was 3.05 
± 0.57 µM. 
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2.4 Conclusions and discussion  
 
Several novel nucleotide mimetics have been found as pH-dependent eN inhibitors in our study. 
eN is upregulated in tumors (Figure 2.828,58). Tumor tissues are hypoxic and have an acidic 
environment.20,28,29,44 The new pH-dependent inhibitors, which can be envisaged as small 
molecules targeting eN in a tumor-selective manner, might be a novel strategy for selective 
tumor therapy.  
 
Figure 2.8. Scheme of purinergic signaling pathways in cancer.28,58 Production of adenosine by 
eN on both local tumor resident cells (TEC) and systemic bone marrow-derived cells 
(CD4+CD25+ regulatory T cells (Tregs)) might modulate anti-tumor responses: on tumor 
resident cells, adenosine decreases expression of adhesion molecule (intercellular adhesion 
molecule-1(ICAM-1), vascular cell adhesion molecule-1(VCAM-1), P-selectin), which results in 
decreasing homing and invasion of effector T cells; and on bone marrow derived cells, adenosine 
decreases expansion and effector functions of T cells. 
 
The most potent pH-dependent inhibitor AMB552.3a was further examined by crystal structure 
analysis. Cocrystal structures of human eN with AOPCP and AMB552.3a are  shown in Figure 
2.9.4 The N-terminal domain contains the metal ion binding site and the C-terminal domain 
contains the substrate binding site, whereby the active site is located at the interface between the 
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N- and C-terminal domains. AOPCP was crystalized with the closed conformation of eN, 
therefore we can see its interaction with the whole active site, whereas AMB552.3a was 
crystallized with the open conformation of eN and we can only see the C-terminal domain 
interaction. The nucleobase of AMB552.3a was tightly sandwiched via π–stacking interactions 
between the side chain of F417 and F500 (adenine clamp), and the uracil base and the ribose 
moieties form hydrogen bonds with the side chains of N390, R395, and D506. Other compounds 
except for AOPCP have not been co-crystallized in the closed conformation of eN,4 in other 
words, we could not examine the interaction of our inhibitors with the N-terminal domain of eN. 
According to our result, both ATP and AMB552.3a, are pH-dependent inhibitors, whereas 
AOPCP is not pH-dependent. Thus we presume that the pH-dependent interaction moiety is 
located in the N-terminal domain. The crystal structure of AMB552.3a probably only reflects 
part of the inhibition mode, because the tail of AMB552.3a is less ordered and sticks out into the 
solvent.  
 
Figure 2.9. Binding mode of AOPCP and AMB552.3a.4 (A) Stereo-view of AOPCP bound to the 
human eN active site of the closed conformation. The two zinc ions are shown as gray spheres. 
The protein residues of the C-terminal domain forming the substrate binding site are shown in 
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green whereas the amino acids of the N-terminal domain are shown in blue. A water molecule, 
which coordinates on metal ions, is shown in red. The AOPCP omit-electron density map is 
shown in blue. (B) Stereo-view of AMB552.3a bound at the human eN C-terminal domain of the 
open conformation. The AMB552.3a omit-electron density map is shown in blue. (C) Schematic 
representation of the interaction of AMB552.3a with the human eN C-terminal domain. 
 
We predicted the pKa values of our pH-dependent inhibitors with the software MarvinSketch 
(Table 6.1), in order to find out the influence of the compounds’ pKa values on their pH-
dependent behaviour. The prediction showed that some inhibitors display changes in 
microspecies distribution in the pH range of 5.0 - 7.4 (e.g. ATP), while some inhibitors have 
stable microspecies distribution in the same pH range (e.g. AMB552.3a), which may lead to the 
conclusion that the different performances of the compounds are not exclusively caused by 
changes in microspecies distribution under different pH conditions. We further confirmed the 
microspecies distribution of AMB552.3a by a potentiometric pKa determination method (Figure 
2.10). The test result was similar to our predicted pKa value.  
 
 
Figure 2.10. Results of potentiometrical pKa determination of AMB552.3a (n=3). The results 
show that in the pH range of 5.0 - 7.4 the ionic charge of compound AMB552.3a is -1. At 
positions 1 and 2, the two carboxylic groups are deprotonated, while at position 3 the tertiary 
amine is protonated. 
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3 Investigation of cerebroside sulfotransferase as therapy target for 
metachromatic leukodystrophy 
3.1 Introduction 
The enzyme cerebroside sulfotransferase (CST) is a promising target for metachromatic 
leukodystrophy (MLD), a rare and severe genetic disease. CST catalyzes the last step in the 
synthesis of cerebroside sulfate (sulfatide), namely the transfer of a sulfate group from 
3′-phosphoadenosine-5′-phosphosulfate (PAPS) to cerebrosides (Fig. 3.1).59 MLD is 
characterized by an accumulation of sulfatide in cells, and this accumulation causes progressive 
destruction of white matter throughout the nervous system.60,61 About 50-60% of MLD patients 
are of the late-infantile form with age onset before 3 years; affected children lose speech, become 
weak, and typically do not survive past childhood. Around 20-30% of MLD patients are of the 
juvenile form with age onset before 16 years of age; affected individuals may survive for about 
20 years after diagnosis. The remaining 15-20% of MLD patients are of the adult form; these 
patients may survive for 20-30 years after diagnosis.60,62 Therapeutic options for MLD include 
enzyme replacement, substrate reduction, stem cell transplantation, and gene therapy.60,63 The 
only conceivable approach allowing the development of small molecules as drugs for MLD 
would be substrate reduction therapy. Therefore we are aiming at developing CST inhibitors to 
reduce the biosynthesis of sulfatide and as a consequence to prevent sulfatide aggregation in the 
central and peripheral nervous system.59  
There are three kinds of published assays for the monitoring of sulfotransferase activity: (i) a 
radioisotopic assay, which monitors the transfer of radioactive sulfate from [35S]-labelled 
3′-phosphoadenosine-5′-phosphosulfate ([35S]PAPS) to cerebroside sulfate (sulfatide), the 
product of CST; [35S]cerebroside sulfate is measured by end-point methods via thin-layer or 
paper chromatography.64–72 (ii) In another assay sphingolipids are quantified by HPLC-MS/MS 
or LC-ESI MS/MS.73–76 (iii) Furthermore, a coupled enzymatic assay was developed, in which 
the auxiliary enzyme aryl sulfotransferase IV (AST-IV) further catalyzes the sulphating of PAP 
with p-nitrophenyl sulfate to form PAPS, and the product p-nitrophenol is monitored.77 The 
drawback of the radioisotopic assay includes the high price of [35S]PAPS and the lengthy 
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procedure associated with thin-layer chromatography, which is not compatible with high-
throughput screening. The main challenge of monitoring sphingolipids is the quantification of all 
sphingolipid species, since they typically consist of a mixture of lipids of different alkyl chain 
lengths, which may additionally contain double bonds and/or hydroxyl groups. Although the 
development of a coupled enzyme assay procedure solved most of the shortcomings of 
previously applied methods, it is still not ideal since inhibitors of the auxiliary enzyme might be 
identified as false-positive hits in CST inhibitor screening. Therefore, a suitable method which 
would allow the direct measurement and quantification of one of the enzymatic reaction products 
would be highly desirable.  
We have now developed a simple, economic, powerful and highly sensitive capillary 
electrophoresis (CE) method for the monitoring of CST activity via quantification of the 
enzymatic product adenosine-3′,5′-diphosphate (PAP) (Fig. 3.1). This is the first validated CE 
method for monitoring of the catalytic activity of the enzyme CST. In order to enhance detection 
sensitivity of PAP, we applied micellar electrokinetic chromatography (MEKC) with polybrene 
as an additive to the running buffer, combined with dynamic pH junction stacking (Figure 3.2). 
Our new CE method enables an efficient separation of the components in the enzyme reaction 
mixture and allows for enzyme kinetic studies, compound library screening, and inhibitor 
characterization.  
 
 
Figure 3.1. Proposed pathway for CST biosynthesis 59. CST can catalyze the conversion of 
cerebroside to sulfatide, and PAPS is sulfate donor, therefore the enzymatic products of CST are 
sulfatide and PAP.  
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Figure 3.2. The dynamic pH junction model based on the results of experiments. The capillary 
was conditioned with BGE buffer (pH 5.6), and then the sample matrix (pH 7.4) was 
electrokinetic injected. The analytes are negatively charged and migrated to detection window 
faster in pH 7.4 buffer than pH 5.6 buffer, therefore a stacking effect occurred on the boundary 
of these two buffers. 
 
Sulfation is a widely observed biological reaction conserved from bacterium to human that plays 
a key role in various biological processes such as growth, development and defense against 
adversities.78,79 Deficiencies due to the lack of the ubiquitous sulfate donor PAPS are lethal in 
humans.78–80 A large group of enzymes called sulfotransferases catalyze the transfer reaction of 
the sulfate group of PAPS to the acceptor group of numerous biochemical and xenochemical 
substrates75,81. Structure-based sequence alignments based on an X-ray crystal structures indicate 
that the PAPS-binding site is conserved.78,79,82 Therefore, the development of competitive 
inhibitors for the CST substrate cerebroside rather than for the co-substrate PAPS may reduce 
side effects that can be expected from competitive inhibitors of the CST co-substrate PAPS. A 
mimic of the transition state-like intermediate state in the cerebroside binding site might 
efficiently inhibit CST catalytic reaction.1 A proposed reaction mechanism between the enzyme, 
the PAPS, and the substrate based on a crystal structure is shown in Figure 3.3,83–85 which might 
give us new ideas about how to design a transition state mimic of a lipid inhibitor.  
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Figure 3.3. Proposed transition state of the substrate according to crystal structures from the 
sulfotransferase family.83–85 The proposed reaction mechanism could be described in two steps: 1. 
The hydroxyl group of the substrate acts as a nucleophile, which when deprotonated by a 
conserved histidine in the active center of the enzyme attacks the sulfur atom of PAPS. 2. The 
formed transition state is subsequently converted to the final product. 
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3.2 Method development and validation 
3.2.1 Development and optimization of the capillary electrophoresis method 
Our goal was to develop a sensitive CE method for monitoring CST reactions. Our group has 
long-standing experience in the quantification of nucleotides by CE, and especially in enzyme 
assays involving the formation or transformation of nucleotides.40,86–92 Thus we decided to 
quantify the nucleotide PAP which is formed from the co-substrate PAPS during the CST 
reaction. This was found to be easier than detecting the lipid sulfatide, which constitutes a 
mixture of compounds with different alkyl chains of different lengths that may additionally 
contain double bonds or hydroxyl groups (see Fig. 3.1). 
As a starting point, a CZE method with borax buffer in fused-silica (FS) capillary was applied. 
However, the CST reaction matrix was high protein-containing and high lipid-containing, we had 
to use centricon to do additional sample preparation step (Figure 3.4): the reaction was stopped 
by filtering the 50 µl reaction solution with 3 kD centricon for 30 min (14,000g). The < 3 kD part 
(around 25 µl) was collected and be measured by CE. 
   
 
Figure 3.4. The electropherogram results for centricon sample preparation. FS Capillary with 40 
cm (30 cm) length and 75 µm internal diameter, 25°C, acquisition rate is 4 Hz, 260 nm detection 
window, running buffer borax 40 mM with pH value 9.1, separation voltage 20 kV, injection 0.5 
psi for 5 sec. A. Without centricon filtration, the peaks of product cannot be detected. B. With 
centricon filtration, the product PAP (retention time 7 min) can be detected.  
 
Since the sample preparation step with centricon was not the optimal way for high throughput 
screening (HTS), we used dynamic coating of the capillary by adding polybrene to running 
buffer, because cationic surfactants can reduce the attachment of proteins and lipids onto the 
fused-silica capillary inner wall, and thereby can support a sweeping effect of negatively charged 
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analytes when a reverse electroosmotic flow (EOF) is applied.87,90,93 This type of MEKC mode 
represents a powerful CE technique,13,93–97 which is especially suitable for charged 
analytes.87,89,90,92,93 In previous studies, the buffers used in combination with polybrene dynamic 
coating of the capillary had a pH range between 2-11, and the most widely used buffers for 
dynamic polybrene coating were borax/boric acid, phosphate, and folic acid, respectively.98–103 
According to the prediction of net charges of PAP and PAPS (Figure 3.5), a pH 8 running buffer 
has firstly been selected. Because at pH 8 there is no net charge difference between PAP and 
PAPS, they can be separated due to the difference in size. We have optimized other parameters, 
e.g. capillary length, in order to achieve good separation (Figure 3.6). The LOD of PAP was 3.09 
µM.  
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Figure 3.5. Prediction of net charges of PAP and PAPS under different buffer pH values 
determined by the software program Marvin Sketch. The prediction showed that that at pH 8, 
there is no net charge differences between PAP and PAPS; whereas at pH 5.6, the net charge 
differences between PAP and PAPS are maximal. Moreover, When PAP migrates from the pH 
7.4 buffer to the pH 5.6 buffer, its net charge is decreased, which will slow down its moving 
velocity and result in a stacking effect at the boundary between these two buffers. 
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Figure 3.6. The electropherogram results with different capillary lengths. 25°C, acquisition rate 
is 4 Hz, 260 nm detection window, running buffer phosphate 75 mM, with 0.002% polybrene, 
pH 8, separation voltage -25 kV, injection -10 kV for 30 sec, PAP and PAPS final concentrations 
were 6.25 µM. Upper curve (in red) was with FS capillary with 50 cm (40 cm); lower curve (in 
black) was with FS capillary with 60 cm (50 cm). 
 
However, we needed a much more sensitive method for the detection of PAP. Therefore we 
further applied dynamic pH junction stacking (see Fig. 3.2). In this method, the stacking is based 
on differences in the analyte’s ionization due to different buffer pH values in the sample matrix 
as compared to the background electrolyte (BGE). 12,104 This results in a velocity difference of 
the analytes in the sample matrix as compared to the BGE thereby causing a stacking effect at the 
boundary of these two buffers.105–113 Both, the coenzyme PAPS and its enzymatic product 
adenosine-3′,5′-diphosphate (PAP) are expected to be negatively charged in buffers of pH values 
ranging between 2-10, and the maximum charge difference between PAPS and PAP was 
predicted to occur at pH 5.6. We further combined dynamic pH junction stacking with MEKC, in 
order to selectively maximize the signal of the enzymatic product PAP. Therefore, a 75 mM 
phosphate buffer of pH 5.6 containing 0.002% polybrene was chosen as the running buffer. 
Electrokinetic injection was used since negatively charged analytes will be selectively injected 
into the capillary by this injection mode.12 Since the more negatively charged analytes will 
migrate faster toward the detection window than the less charged analytes (due to the addition of 
the cationic surfactant polybrene causing a reversal of the electroosmotic flow (EOF)), the 
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velocity of PAP will be faster at pH 7.4 (where it has a higher negative charge) than at pH 5.6 
buffer. Therefore PAP will stack at the boundary of these two buffers, when it migrates from the 
pH 7.4 buffer to the pH 5.6 buffer zone. We achieved this pH junction stacking effect simply by 
an additional sample preparation step: the CST reaction samples were dissolved in 5 mM 
phosphate buffer, pH 7.4, containing 0.0001% polybrene, before transferring them into the CE 
sample vials and subsequently eluted with the running buffer of pH 5.6 (75 mM phosphate 
buffer). An additional benefit of this procedure is the field amplifying sample stacking (FASS) 
effect due to significant differences in buffer concentration (ionic strength of sample matrix as 
compared to BGE (see Figure 3.10).12,95,96,106,114 
In the next step, several parameters of the CE measurements were further optimized. We 
investigated different separation voltages (15-25 kV), injection volumes (6-10 kV, 10-60 s), and 
capillary lengths (40 cm and 50 cm effective length). A voltage of -15 kV yielded the best 
compromise in terms of migration time, current generated, and separation efficiency. In order to 
improve resolution and at the same time maximizing the injection amount, an electrokinetic 
injection at -10 kV for 30 s was chosen. The longer capillary which enabled a better separation of 
the analytes, was preferred. Finally, we achieved a clear separation between the coenzyme PAPS 
and the enzymatic product PAP through pH-stacking (Fig. 3.7-3.9). The identity of each peak 
was confirmed by spiking with reference compounds.  
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Figure 3.7. Representative electropherogram of cerebroside sulfotransferase (CST) reactions. (A) 
The CST reaction in the presence of the CST inhibitor Congo Red (600 µM). (B) CST reaction 
without inhibitor. Peaks: 1, PAPS; 2, PAP; 5, I.S. GDP; 3 and 4, impurities of PAPS. 
 
 
 
Figure 3.8. PAP 1 µM peak with pH-stacking (B. in pH 5.6 BGE) and without pH-stacking (A. 
in pH 8 BGE). peak 1 and 3: PAP; peak 2 and 4: I.S. 
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Figure 3.9. The pH stacking effect compared between pH 6.5 BGE (A) and pH 5.6 BGE (B). 
peak 1 and 4: PAPS; peak 2 and 5: PAP, peak 3 and 6: I.S. 
 
 
 
 
Figure 3.10. Field amplifying stacking effect due to significant differences in buffer 
concentration. BGE: 75 mM phosphate buffer of pH 5.6 containing 0.002% polybrene. A. 
Stacking buffer 5 mM phosphate buffer of pH 7.4 containing 0.0001% polybrene; B. Stacking 
buffer 75 mM phosphate buffer of pH 7.4 containing 0.002% polybrene; C. 10 mM HEPES with 
16 mM MgCl2, pH 7.1. The result showed that only when the stacking buffer and BGE buffer 
were both phosphate buffers containing polybrene, and the stacking buffer concentration was 
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lower than that of the BGE buffer (in this case, 15 folds lower), a field amplifying stacking effect 
could be achieved. With HEPES buffer (C) a field amplifying stacking effect could not be 
observed. peak 1: PAPS; peak 2: PAP, peak 3: I.S. 
3.2.2 Calibration and validation of the capillary electrophoresis method 
The newly developed CE method was validated according to the guidelines published by the 
International Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, and the US Food and Drug Administration (FDA), 
respectively.10,11 A summary of the parameters of method validation is provided in Table 3.1. A 
strictly linear correlation between analyte concentration and peak-area ratio of analyte to I.S. was 
observed from 0.0625 µM to 1.25 µM for PAP. LOD and LOQ for PAP were 66.6 nM (LOD) 
and 202 nM (LOQ), which demonstrating good sensitivity of the new method. Accuracy and 
precision were within an acceptable range for the measurement of low concentrations of 
analytes.10,11 The validation of the CE method demonstrated its suitability for the analysis of 
enzyme kinetics and for inhibitor testing. To the best of our knowledge, our CE method is the 
first validated testing system for morning CST catalytic activity. 
 
Table 3.1. Quantification and method validation of CST reaction product 
Parameters Regression equation (n=5) R
2 
LOD (nM) 
(Sy.x/slope)*3.3 
LOQ (nM)  
(Sy.x/slope)*10 
Adenosine -
3′,5′-
diphosphate 
(PAP) 
y = 45.63 x - 0.61 
(Calibration range: 
0.0625 - 1.25 µM) 
0.998 66.6 202 
PAP Conc 
(µM) 
Validation of PAP 
Accuracy 
(n = 5, % recovery) 
Accuracy 
acceptable rangea 
Precision 
(n = 5, 
RSDb %) 
Precision 
acceptable 
rangea 
0.0625 112.4 80-120% 12.4 20% 
0.125 96.5 80-120% 3.1 20% 
0.25 97.2 80-120% 6.8 20% 
0.625 100.6 80-120% 5.9 20% 
1.25 99.9 80-120% 1.9 20% 
 
a According to guidelines of the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 10 
b Relative standard deviation 
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3.3 Results 
3.3.1 Kinetic characterization and inhibition assays for cerebroside sulfotransferase 
with reference compounds 
 
The linear range of the CST reaction with cerebroside was determined under different conditions 
(Figure 3.11).  
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Figure 3.11. Determination of CST-catalyzed reaction. The concentration of cerebroside was 
kept at 100 µM, and a linear rang was found to be under the following conditions: (i) the linear 
range was 60 min, when the PAPS concentration was 30 µM, with 6.25 µl CST (per 50 µl 
reaction vial); (ii) the linear range was 60 min, when the PAPS concentration was 100 µM, with 
3.125 µl CST (per 50 µl reaction vial); (iii) the linear range was 30 min, when the PAPS 
concentration was 30 µM, with 3.125 µl CST (per 50 µl reaction vial). The result indicates that, 
the linear range increased when the enzyme amount was higher or when the substrates 
concentrations were higher.  
 
 
 
Apparent enzyme kinetics parameters (Michaelis-Menten constant and maximal velocity) were 
determined for the reference substrates cerebroside and phychosine (Fig. 3.8).64,66,69,115,116 
Cerebroside displayed a Km value of 60.3 µM and a Vmax value of 0.0738 µmol/min/mg, which is 
well in agreement with reported results (Km values of 26-52 µM 64,66,69,115,116). For psychosine a 
Km value of 103 µM and a Vmax value of 0.105 µmol/min/mg was determined, in the same range 
as that for cerebroside. To our knowledge, this is the first determination of a Km value for 
psychosine. 
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Next we used the new CE method to characterize the reported CST inhibitor Congo Red,65 and 
an IC50 value of 38.1 µM was determined (Fig. 3.9). Moreover, we analyzed the inhibition 
mechanism with respect to the substrate cerebroside. Congo Red had previously been reported to 
be a competitive inhibitor with respect to the CST co-substrate PAPS.65 In our studies we 
showed that it acted as an uncompetitive inhibitor with respect to the CST substrate cerebroside 
displaying an αKi value of 29.6 µM. Our results are well in agreement with the published data 
(Ki = 41 µM, competitive versus PAPS 65). Our study represents the first determination of the 
inhibition type of a CST inhibitor versus the substrate cerebroside.  
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Figure 3.12. Enzyme kinetics of CST with cerebrosides and psychosine. (A) Michaelis-Menten 
plot for cerebrosides, Km = 60.3 ± 21.7 µM, Vmax = 0.0738 ± 0.0039 µmol/min/mg; (D) 
Michaels-Menten plot for psychosine, Km = 103 ± 11 µM, Vmax = 0.105 ± 0.018 µmol/min/mg. 
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Figure 3.13. Characterization of the cerebroside sulfotransferase (CST) inhibitor Congo Red. (A) 
Concentration-inhibition curve of Congo Red (IC50 38.1 ± 6.5 µM); (B) Lineweaver-Burk plot 
for Congo Red versus the CST substrate cerebroside. Congo Red showed an uncompetitive 
mechanism of inhibition versus cerebroside with a Ki value of 29.6 µM. 
 
 
3.3.2 Kinetic characterization of cerebroside sulfotransferase-catalyzed reactions with 
artificial substrates 
We tested a group of carefully selected analogues of the natural CST substrate 
galactocerebroside. Altogether, 14 compounds were investigated as potential artificial substrate 
of CST (see Table 6.4). Enzyme kinetic parameters (Michaelis-Menten constant and maximal 
velocity) were determined for all identified artificial substrates (Table 3.2). 
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Table 3.2. Testing of galactocerebroside analogues as potential substrate of CST 
 
Compound 
 
Structure 
 
 
Km (µM) 
Vmax 
(µmol/ml/min) 
 
kcat/Km 
 
 
β-glycolipids  
 
 
 
cerebroside 
(reference) 
 
 
60 
 
 
0.0738  
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psychosine 
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0.105  
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3.3.3 Inhibitors of cerebroside sulfotransferase 
13 compounds were investigated for searching competitive inhibitor versus cerebroside and 
KRN7000 (see Table 6.4), IC50 values versus the natural substrate cerebroside and the artificial 
substrate KRN7000 are shown in Table 3.3.  
 
Table 3.3. Inhibition testing of CST 
 
Compound 
 
Structure 
IC50 ± SEM (µM)a 
(to cerebrosides) 
(inhi% at 100 µM) 
IC50 ± SEM (µM) 
(to KRN7000) 
(inhi% at 100 µM) 
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aThe substrate concentration for inhibition testing was 100 µM, the concentration of the cofactor 
PAPS was 30 µM. 
bThe substrate concentration for inhibition testing was 466 µM, the concentration of the cofactor 
PAPS was 30 µM. 
 
 
 
3.3.4 Structure-activity relationship study of the cerebroside sulfotransferase 
cerebroside binding site 
 
Regarding the structure-activity relationship study of the CST cerebroside binding site, two 
critical points were discovered: The stereochemistry at the 1-, 4-, and 5-positions of 
galactocerebroside dramatically influences the activity of CST, and the lipid moiety can also 
have an effect on the CST activity. Details are shown as below: 
 
 
Figure 3.14. Interaction sites of substrate and co-substrate in the catalytic site of CST 
 
1. Domain I was reported to bind PAPS (see Figure 3.3).83–85 
2. Domain II around the sugar head should be highly specific.   
 Position 1: β-glycosides can fit into the enzyme active site better than α-
glycosides (β-glycosides have smaller Km values, see Table 3.2); and β-glycosides 
could be better catalyzed in the CST active site (β-glycosides have larger kcat/Km 
values, see Table 3.2), which is in agreement with the previous study (The 
previous study showed that CST prefers β-glycosides 64).  
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 Position 4: glucocerebrosides can inhibit cerebrosides (see Table 3.2), which 
shows that the position 4 is crucial in the active site, which is in agreement with 
the previous study (The previous study showed that glucocerebrosides, Gg4Cer, 
Gb4Cer and nLc4Cer are not substrates 64 ). 
 Position 5: NP230 is neither substrate, nor inhibitor, which shows that in position 
5 there is a space limitation (see Table 6.4). 
3. Domain III around the lipid tail appears to be specific, because lipids with different chain 
lengths showed diverse activities (see Table 3.2).  
 
 
 
 
 
3.4 Conclusions and discussion  
We developed and validated a sensitive and robust test system for the enzyme cerebroside 
sulfotransferase (CST), which constitutes a potential target for the treatment of metachromatic 
leukodystrophy (MLD). The new CE-based method was shown to be suitable for performing 
enzyme kinetic studies, for inhibitor screening and Ki value determination. The CE method 
utilizes a sample matrix consisting of 5 mM phosphate buffer with 0.0001 % polybrene at pH 7.4 
and a BGE consisting of a 75 mM phosphate buffer with 0.002 % polybrene at pH 5.6, to induce 
a dynamic pH junction-sweeping stacking effect for the enzymatic product PAP leading to a low 
detection limit (LOD = 66.6 nM). Several reference compounds were tested including the 
substrates cerebroside and psychosine and the inhibitor Congo Red in order to further validate 
the method.  
We tested a group of carefully selected analogues of CST nature substrate galactocerebroside. 
We obtained detailed SAR information for the CST cerebroside binding site by analyzing 
numeral artificial substrates, and novel competitive CST inhibitor versus galactocerebroside has 
been found. Inhibitory effects on CST was observed with several compounds, and concentration-
inhibition curves were determined for the most potent inhibitor C16 (Table 3.3). C16 was found 
to be the first competitive inhibitor versus galactocerebroside, with an IC50 340 µM, and an IC50 
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328 µM versus artificial CST substrate KRN7000, respectively. Moreover, glucocerebrosides 
and β-KRN7000 showed significant inhibition (70%) of CST activity at a test concentration of 1 
mM (see Table 3.3). The new CST inhibitor C16 can be the lead structure and be further 
optimized for potent CST inhibitors, which are urgently needed for the treatment of MLD. Our 
ultimate goal is to develop CST inhibitors for substrate reduction therapy to help young MLD 
patients to survive this devastating genetic disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
4 Analysis of the Staphylococcus aureus capsule biosynthesis 
pathway  
4.1 Introduction 
Staphylococcus aureus is an opportunistic bacterial pathogen responsible for a diverse spectrum 
of human and animal diseases, and it is also major cause of wound infections. Since capsules 
enhance microbial virulence by rendering the bacterium resistant to phagocytosis, many 
microorganisms that cause invasive disease produce extracellular capsular polysaccharides. 
Inhibitors targeting capsule biosynthesis may have the potential for use in combination 
therapeutics.117,118 Inhibition of capsule formation would also unmask patterns on the bacterial 
cell surface, which are important for pathogen recognition and clearance by the innate immune 
system. S. aureus strains are classified into 11 capsular serotypes, and most clinical isolates of S. 
aureus correspond either to type 5 (CP5) or type 8 (CP8).119 CP5 has the structure (→4)-3-O-Ac-
β-D-ManNAcA-(1→4)-α-L-FucNAc-(1→3)-β-D-FucNAc-(1→)n; CP8 only differs in the 
glycosidic linkages between the sugars  and the sites of O-acetylation.119,120 The biosynthesis of 
S. aureus CP5 is facilitated by several highly conserved enzymes, including enzymes CapD and 
CapE which catalyze the conversion of UDP-D-GlcNAc to UDP-2-acetamido-2,6-dideoxy-D-
xylo-4-hexulose and UDP-2-acetamido-2,6-dideoxy-L-lyxo-4-hexulose, respectively.120 The 
biosynthesis of S. aureus CP5 is shown as below: 
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Figure 4.1. Proposed pathway for S. aureus CP5 biosynthesis (adapted from O’Riordan & Lee, 
2004 121). CapD and CapE catalyze the conversion of UDP-D-GlcNAc to UDP-2-acetamido-2,6-
dideoxy--D-xylo-4-hexulose, and UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose, 
respectively. 
 
In order to study the catalytic activities of CapD and CapE at the molecular level, we developed 
and optimized a capillary electrophoresis (CE)-based detection method. CE is a simple, 
economic and powerful method for monitoring enzyme reactions, especially those that are 
generating charged products.87,89,90,92 A CE method for studying CapE activity has been 
described using borax buffer pH 9 as a running buffer, and hydrodynamic injection.120,122 We 
have now developed a considerably improved method, which is faster, more sensitive and robust, 
enabling efficient separation of the components in the enzyme reaction mixture and allowing for 
enzyme kinetic studies, compound library screening, and inhibitor testing. The new CE method 
is based on micellar electrokinetic chromatography (MEKC), in which surfactants are used as 
running buffer additives. Recently, CE approaches using cationic surfactant as dynamic coatings 
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on silica-fused capillaries have gained considerable interest, because they allow a significant 
improvement in detection sensitivity.87,90 The addition of cationic surfactants to the running 
buffer causes the reversal of the electroosmotic flow (EOF) due to adsorption of these surfactants 
to the capillary wall thereby creating a positively charged surface. With this setup, EOF and 
migration of negatively charged analytes are both directed towards the positive electrode. The 
use of the polycationic polymer polybrene (PB) for dynamic coating results in an effective 
stacking of sample zones due to its sweeping effect.90,123 Because of the strong preconcentration 
effects of polycationic polymers, the detection limits of analytes may be strongly improved, 
down to the nanomolar range.87,90 The newly developed method is much faster and significantly 
more sensitive compared to the previously reported procedure and allows for the screening of 
compound libraries in search of inhibitors. 
 
4.2 Method development and validation 
4.2.1 Development and optimization of capillary electrophoresis method  
A sensitive analytical method for monitoring the catalytic activities of capsule biosynthetic 
enzymes was required, which would not only allow characterization of the enzymatic reactions, 
but also be suitable for the screening of inhibitors. Since both, substrate (UDP-D-GlcNAc) and 
products (UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose and UDP-2-acetamido-2,6-
dideoxy-β-L-arabino-hex-4-ulose), of CapD and CapE are negatively charged in alkaline buffer, 
we chose CE separation applying a micellar electrokinetic chromatography (MEKC) mode and 
reverse electroosmotic flow (EOF) for detection. The choice of the buffer is crucial for obtaining 
clear and narrow peaks without producing excessive Joule heating. The prediction of charge 
differences between substrate and products is helpful for choosing a suitable pH value for the 
running buffer, and this was accomplished by means of the Marvin Sketch software (ChemAxon, 
Hungary) (Figure 4.2).  
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Figure 4.2. Prediction of net charges of analytes under different buffer pH values 
 
As shown in Figure 4.2, a high pH value was predicted to be favourable for obtaining net charge 
differences between substrate and products. However, when the separation buffer pH value is too 
high, excessive Joule heating may destroy the capillary detection window after a few runs. To 
balance these two factors, a pH value of 12.4 was predicted to provide optimal conditions. 
Therefore, 3-(cyclohexylamino)-1-propane sulfonic acid (CAPS, 68 mM) buffer was chosen, 
which covers the high pH range. The combination of CAPS with the detergent polybrene 
(hexadimethrine bromide, 0.002%) represents a new combination in MEKC. To confirm that this 
CE method allows the separation of UDP-D-GlcNAc from the CapD enzymatic product, the 
recently described PglF reaction was analyzed.122 PglF from C. jejuni had been demonstrated to 
catalyze the 4,6-dehydratation of UDP-D-GlcNAc yielding UDP-2-acetamido-2,6-dideoxy-α-D-
xylo-hex-4-ulose,122 the same product as proposed for the CapD-mediated reaction. In vitro 
reconstitution of PglF catalytic activity was performed using a soluble derivative of the native C. 
jejuni membrane protein lacking transmembrane domains as originally described by 
Schoenhofen et al.122 As predicted, the PglF-His6 enzymatic product migrated faster in the 
capillary than UDP-D-GlcNAc as a result of a reduced net negative charge (Figure 4.3). The 
enzymatic activity of CapE can be analyzed using the same method, since its product 120 is a 
stereoisomer (diastereomer) of UDP-2-acetamido-2,6-dideoxy--D-xylo-4-hexulose and thus 
displays almost very similar CE migration behavior. To increase the sensitivity and to achieve 
faster separation of the analytes enabling high throughput screening, the CE method was further 
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optimized. To this end, we investigated different separation voltages (15-25 kV), injection 
volumes (1-5 kV, 5-30 s), and capillary lengths (30 cm and 50 cm effective length). A voltage of 
-15 kV yielded the best compromise in terms of migration time, current generated and separation 
efficiency. In order to improve peak shape and sensitivity, different injection times and injection 
voltages were applied. A small injection voltage was found to be beneficial for high accuracy 
and an electrokinetic injection at -1 kV for 20 s was chosen. Two different capillary lengths (30 
cm or/and 50 cm effective length) were compared in terms of CE performance. The long 
capillary enabled better separation of analytes and was therefore preferred.  
In recent years MEKC has been developed as a powerful CE technique.13,94–97 In previous studies, 
the buffers used in combination with polybrene dynamic coating of the capillary had a pH range 
between pH 2 and pH 11, and the most widely used buffers for dynamic polybrene coating were 
borax, boric acid, phosphate, and folic acid.98–103 A high pH CAPS buffer has not been 
previously used in combination with dynamic polybrene coating of the capillary. With 
CAPS/polybrene as a running buffer, analytes will migrate towards the detection window 
depending on their negative charge, with faster migration observed with higher negative charge. 
Moreover, by electrokinetic injection, a high quantity of negatively charged analytes can 
selectively be injected into the capillary,12 leading to increased concentrations of anionic analytes. 
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Figure 4.3. Representative electropherograms of CapD (A) and PglF (B) reactions. CAPS buffer 
(68 mM) containing polybrene (0.002%), pH 12.4, electrokinetic injection (-1 kV, 20sec), λmax = 
260 nm, separation voltage = -15 kV. Uncoated fused-silica capillaries of 60 cm total length (50 
cm effective length) × 75.5 µm (inner diameter) × 363.7 µm (outer diameter). Peaks: 1, UDP; 2, 
NADP impurity; 3, I.S. PAP; 4 and 5, NADP impurities; 6, product UDP-2-acetamido-2,6-
dideoxy--D-xylo-4-hexulose; 7, substrate UDP-D-GlcNAc and cofactor NADP. 
 
CE analysis of the quenched CapD reaction mixture revealed a peak with identical UV spectrum 
and retention time as observed for the PglF enzymatic product (Figure 4.3), which was further 
confirmed by MS: a molecular mass of 588.3 (negative mode; [M – H]-) was determined for the 
HPLC-purified CapD and PglF reaction products, consistent with the expected mass of 589.3 for 
UDP-2-acetamido-2,6-dideoxy--D-xylo-4-hexulose. The identity of each peak in CE 
electropherogram was confirmed by spiking with reference compounds. In contrast to CapE, 
which displayed full in vitro activity without externally added cofactors, CapD activity was 
dependent on the presence of detergent and NADP; addition of NAD or the absence of any 
cofactor resulted in less than 5% substrate conversion (Figure 4.4).  
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Figure 4.4. CapD cofactor dependency. CapD activity was dependent on the presence of NADP; 
addition of NAD or the absence of any cofactor resulted in less than 5% substrate conversion to 
product UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose. Enzyme reaction incubated at 30°C 
for 2 hours, containing 3 mM UDP-D-GlcNAc and 2 mM NAD/NADP or no cofactor. 
 
4.2.2 Calibration and validation of the capillary electrophoresis method 
 
Since UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose and UDP-2-acetamido-2,6-dideoxy-
β-L-arabino-hexos-4-ulose are not commercially available, we used enzymatic products for 
calibration to allow for product quantification. For CapD assays, the CE system was calibrated 
and validated with the PglF enzymatic product (100% substrate conversion). For CapE assays, 
the CE system was calibrated and validated with the CapE product UDP-2-acetamido-2,6-
dideoxy-β-L-arabino-hex-4-ulose (100% substrate conversion). Since the nucleotide-activated 
sugars in the reaction mixture were partially hydrolyzed, the degradation product UDP was 
quantified to determine the actual concentration of PglF and CapE enzymatic product (at 100% 
substrate conversion).  
The newly developed CE method was validated according to the guidelines published by the 
International Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, and the US Food and Drug Administration (FDA), 
respectively.10,11 A summary of the parameters of method validation is provided in Table 4.1. A 
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strictly linear correlation between product concentration and peak-area ratio of product to I.S. 
was observed from 0.22 µM to 7.09 µM for the CapD product and from 0.33 µM to 5.34 µM for 
the CapE product. LOD and LOQ for both products were nearly identical: 0.71 µM (LOD) and 
2.15 µM (LOQ) for the CapD product, and 0.81 µM (LOD) and 2.45 µM (LOQ) for the CapE 
product thus demonstrating high sensitivity of the new method. Accuracy and precision were 
within an acceptable range for the measurement of low concentrations of analytes.10,11 The 
validation of the CE method demonstrated its suitability for the analysis of enzyme kinetics and 
for inhibitor testing. 
 
Table 4.1. Quantification of CapD and CapE reaction products: method validation 
 
 
Parameters 
CapD product 
UDP-2-acetamido-2,6-dideoxy- 
α-D-xylo-hex-4-ulose
CapE product 
UDP-2-acetamido-2,6-dideoxy- 
β-L-arabino-hex-4-ulose 
 
 
 
 
 
Regression 
equation 
(n=6) 
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R2 0.9927 0.9801 
LOD (µM) 0.71 0.81 
LOQ (µM) 2.15 2.45 
Calibration 
range (µM) 
 
0.22 - 7.09 
 
0.33 - 5.34 
 Concentration 
(µM) 
Accuracy 
(n=6, % 
recovery) 
Accuracy 
acceptable 
rangea 
Precision 
(n=6, RSDb 
%) 
Precision 
acceptable 
rangea 
 
C
ap
D
 
pr
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0.44 100.9 80-120% 14.4 20% 
0.89 100.4 80-120% 2.3 20% 
3.55 101.0 80-120% 5.4 20% 
7.09 99.9 80-120% 7.0 20% 
 
C
ap
E 
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od
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t 
 
0.67 100.9 80-120% 4.4 20% 
1.34 93.6 80-120% 7.0 20% 
2.67 101.5 80-120% 11 20% 
5.35 99.9 80-120% 11 20% 
a According to guidelines of the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 10   
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b Relative standard deviation 
 
Previously reported CE methods for the detection of UDP-2-acetamido-2,6-dideoxy-α-D-xylo-
hex-4-ulose and UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose used 25 mM borax 
buffer, pH 9.4 or 9.5, and hydrodynamic injection.121,122 The LOD and LOQ values for UDP-2-
acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose for the previously published method 122 were 7.3 
µM and 22.2 µM, respectively. With our new method, the migration time of UDP-2-acetamido-
2,6-dideoxy-α-D-xylo-hex-4-ulose was reduced by 50% (from 18 min to 9 min), while the LOD 
was improved by 10-fold from 7.3 µM to 0.71 µM (Figure 4. 5).  
 
Figure 4.5. Electropherograms for methods comparison. Electropherograms obtained with the 
previously published method (A) and with the new method (B). (A) 68 mM CAPS buffer 
containing polybrene 0.002%, pH 12.4, electrokinetic injection (-1 kV, 20sec), λmax = 260 nm, 
separation voltage = -15 kV. Uncoated fused-silica capillaries of 60 cm total length (50 cm 
effective length) × 75.5 µm (id) ×363.7 µm (od). (B): 25 mM borax buffer, pH 9.4, 
hydrodynamic injection (0.5 psi, 10 sec), λmax = 260 nm, separation voltage = 18 kV. Uncoated 
fused-silica capillaries of 60 cm total length (50 cm effective length) × 75.5 µm (id) ×363.7 µm 
(od). A and B chromatograms are shown at the same scale. Peaks: 1, buffer; 2, I.S. Uridine; 3, 
product of Pg1F by using the published method; 4, UDP; 5, I.S. PAP; 6, product of Pg1F by 
using the new method. 
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4.3 Results and discussion 
4.3.1 Kinetic characterization of CapD- and CapE-catalyzed reactions. 
Enzyme kinetics (Michaelis-Menten constant and maximal velocity) were determined for both 
CapD and CapE (Figure 4.6). CapD displayed a Km value of 3650 ± 270 µM and a Vmax value of 
0.127 ± 0.011 µmol/min/mg. For CapE, a Km value of 457 ± 76 µM and a Vmax value of 0.071 ± 
0.004 µmol/min/mg were determined. The CapD in vitro reaction was in the linear range (steady-
state phase) for up to 120 min, whereas CapE measurements were in the linear range for 60 min 
under the conditions applied. 
 
Figure 4.6. Enzyme kinetics of CapD and CapE. Time-dependent enzymatic reaction of CapD (A) 
and CapE (B). (C) Michaelis-Menten plot for CapD, Km 3650 ± 270 µM, Vmax 0.127 ± 0.011 
µmol/min/mg; (D) Michaels-Menten plot for CapE, Km 457 ± 76 µM, Vmax 0.071 ± 0.004 
µmol/min/mg. 
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4.3.2 Inhibitors of CapD and CapE 
 
We tested a series of selected small molecules including uracil nucleotide derivatives,92,124 
compounds known to bind to nucleotide binding sites 125 and clinically applied antibiotics. 
Altogether, 73 compounds were investigated for CapD inhibition, and 46 compounds were 
screened for inhibition of CapE (Table 6.1 and Table 6.2). Inhibitory effects on CapD or CapE 
were observed with several compounds, and concentration-inhibition curves were determined for 
the most potent inhibitors (Figure 4.7). Suramin 126 was found to be a potent CapE inhibitor with 
an IC50 value of 1.82 ± 0.40 µM, whereas CapD was not inhibited at a test concentration of 10 
µM. Intriguingly, the ß-lactam antibiotic ampicillin efficiently inhibited CapD enzymatic activity 
(IC50 40.1 ± 14.9 µM). Beta-lactam antibiotics interfere with bacterial peptidoglycan (PG) 
biosynthesis by inhibiting penicillin-binding proteins (PBPs) and thus the transpeptidation of cell 
wall building blocks.127 The ß-lactam ring structurally mimics the D-Ala-D-Ala terminus of the 
pentapeptide side chain that is attached to the MurNAc moiety of the central PG precursor lipid 
II. Because of this structural analogy, we investigated the effects of different cell wall precursor 
molecules on CapD enzymatic activity. The pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala was 
found to inhibit CapD enzymatic activity with an IC50 value of 73.9 ± 12.8 µM. Moreover, lipid 
II showed significant inhibition (67%) of CapD activity at a test concentration of 100 µM. Both, 
ampicillin and lipid II, were found to be selective inhibitors of CapD. Concentration inhibition 
curves for suramin at CapE, and the pentapeptide (side chain) and ampicillin at CapD are shown 
in Figure 4.7. Furthermore, the inhibition mechanisms for suramin, ampicillin and the 
pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala were investigated (Figure 4.8). Suramin was 
found to act as a non-competitive inhibitor at CapE.  Ampicillin appeared to be a non-
competitive inhibitor at CapD while the pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala showed 
a competitive inhibition mechanism at CapD. 
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Figure 4.7. Concentration-dependent inhibition of CapD and CapE. (A) CapE inhibition by 
suramin (IC50 1.82 ± 0.40 µM); (B) CapD inhibition by ampicillin (IC50 40.1 ± 14.9 µM); (C) 
CapD inhibition by the pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala (IC50 73.9 ± 12.8 µM). 
Substrate concentration was 1 mM.  
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Figure 4.8. Determination of enzyme inhibition mechanism. (A) CapE inhibition by suramin is non-
competitive (suramin concentations for determination were 0.1 µM, 0.5 µM and 1 µM); (B) CapD 
inhibition by ampicillin is non-competitive (ampicillin concentations for determination were 0 µM, 15 
µM and 75 µM); (C) CapD inhibition by the pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala is 
competitive (pentapeptide concentations for determination were 25 µM, 750 µM and 2500 µM).  
 
To determine whether the inhibitory effects of ampicillin on CapD would translate into an effect 
on CP5 production, a testing in vivo was followed up.93 The S. aureus strains Reynolds were 
grown in the presence and absence of ampicillin. CP5 products by the S. aureus strain Reynolds 
were evaluated at ampicillin concentrations ranging from 67 – 270 µM. Concentrations up to 270 
µM (100 µg/ml) ampicillin can be achieved in vivo 128. Like the majority of S. aureus strains, 
Reynolds is resistant to ampicillin and penicillin, and the minimum inhibitory concentration of 
ampicillin for Reynolds is >128 µg/ml. After overnight incubation, the treated and untreated 
staphylococci were washed and treated with trypsin to remove protein A. Serial dilutions of the 
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bacterial suspensions were incubated overnight with CP5-specific rabbit serum. The absorbed 
sera were then tested on a microtiter plate coated with purified S. aureus CP5. The CFU/ml that 
resulted in 50% binding compared to the unabsorbed serum was calculated. Growth in the 
presence of ampicillin inhibited CP5 production, as 3.6- to 5.9-fold higher bacterial 
concentrations were required to achieve an IC50 value comparable to the culture cultivated in the 
absence of ampicillin (Figure 4.9). CP5 production by S. aureus grown in media containing 270 
µM ampicillin (100 µg/ml) was evaluated six times, and these experiments indicated that a 
bacterial concentrationof  8.6 ± 2.9 (average ± SEM) fold higher than that of the antibiotic-free 
culture were required to achieve 50% inhibition of antibody binding. 
 
 
Figure 4.9. ELISA inhibition experiment showing that CP5 production by S. aureus Reynolds is 
inhibited when the culture is incubated in the presence of ampicillin (Amp). The binding ratio is 
calculated by comparing the OD405 nm of the serum samples incubated with different bacterial 
concentrations with that of the serum sample containing no bacteria. For quantitation, the 50% 
inhibitory bacterial concentration was compared between cultures grown in the presence or 
absence of ampicillin (CFU, colony-forming units). 
 
4.3.3 CapAB kinase complex regulates capsule biosynthesis  
We investigated the role of the tyrosine kinase complex CapAB in the regulation of CapD and 
CapE. We identified CapE as regulatory target of the CapAB kinase complex and show that 
tyrosine phosphorylation enhances its catalytic activity in vitro. To study the impact of CapAB 
mediated phosphorylation on CapE enzymatic activity, CapE assays were performed in the 
presence of either active or of heat-inactivated CapAB kinase complex, as shown in Figure 4.10. 
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The conversion of UDP-D-GlcNAc was increased in the presence of active CapAB, indicating 
that the CapE catalyzed reaction is positively modulated through phosphorylation. We tried 
different batches of CapE enzymes, CapAB activated CapE in a stable way (Figure 4.10). Further 
testing with CapE mutations have been carried out with the same method. 
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Figure 4.10. CapAB kinase complex regulates CapE. CapE was incubated in presence of either 
active CapAB (gray) or heat-inactivated CapAB (black) with UDP-D-GlcNAc for 30 min. 
Reactions were analyzed by CE.  
4.3.4 In vitro reconstitution of UDP-D-FucNAc biosynthesis 
Homology searches with CapD and CapN suggested that both proteins are involved in the 
synthesis of the first soluble capsule precursor UDP-D-FucNAc.121 More recently, CapD enzyme 
was characterized at the molecular level, and the enzymatic product was shown to be UDP-2-
acetamido-2,6-dideoxy-D-xylo-4-hexulose (unpublished data). CapN is proposed to further 
convert the CapD reaction product to UDP-D-FucNAc by stereospecific reduction of the C-4 
keto group.121  
For analysis of the CapN reaction, a CE method described by Kneidinger et al.120 was applied. 
As shown in Figure 4.11, purified recombinant CapN-His6 was able to convert UDP-2-
acetamido-2,6-dideoxy-D-xylo-4-hexulose (retention time 15.45 min) into a new carbohydrate 
species displaying altered CE migration behavior (retention time 14.53 min); no such peak was 
observed with the heat-inactivated negative controls (Figure 4.11). In good agreement with the 
studies of Kneidinger et al. on UDP-L-FucNAc biosynthesis, CapN enzymatic product migrated 
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faster in the capillary than PglF enzymatic product, but slower than UDP-D-GlcNAc (retention 
time 13.88 min). Analogous results were obtained using CapD enzymatic product as substrate for 
CapN reactions. CapN enzymatic activity was dependent on the addition of NADPH; no 
conversion was observed in the absence of externally added cofactors. Utilization of NADH as 
cofactor could not be tested as the NADH preparation produced some minor peaks in CE 
analysis, migrating at the height of the enzymatic product. The HPLC purified PglF and CapN 
enzymatic products were subjected to Maldi-TOF mass spectrometry and molecular masses of 
588.1 and 590.4 (negative mode; [M – H]-) were determined, in accordance with the expected 
neutral masses of 589.3 and 591.4 for UDP-2-acetamido-2,6 dideoxy-D-xylo-4-hexulose and 
UDP-D-FucNAc, respectively. These results confirm that CapN functions as a reductase and, 
using NADPH as a cofactor, is able to convert the substrate UDP-2-acetamido-2,6-dideoxy-D-
xylo-4-hexulose to form the first soluble capsule precursor UDP-D-FucNAc.  
 
 
Figure 4.11. Capillary electrophoresis (CE) analysis of CapN in vitro activity. Purified CapN and 
PglF were incubated simultaneously in a combined assay in the presence of UDP-GlcNAc and 
NADPH. (A) PglF/CapN reaction. (B) Control reaction, CapN heat inactivated. 1; UDP-GlcNAc; 
2, UDP-FucNAc (CapN product); 3, UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose (PglF 
product); 4, NADP.   
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4.4 Conclusions and discussion  
The enzymatic reactions involved in the syntheses of the soluble capsule precursors UDP-L-
FucNAc and UDP-D-ManNAcA have already been studied in vitro.120,129,130 However, in vitro 
characterization of the biosynthesis of the first soluble capsule precursor (UDP-D-FucNAc) has 
long been hampered by the fact that CapD, the enzyme catalyzing the initiating step, is a protein 
with multiple transmembrane domains. We have now been able to reconstitute CapD enzymatic 
activity in vitro and characterize the full-length membrane protein at the molecular level with our 
new CE method, thus providing the basis for future reconstitution of the complete biosynthetic 
pathway. 
Since established antibiotics are becoming increasingly inefficient, there is an urgent need to 
explore new treatment strategies to counteract drug-resistant pathogens.131 Capsule biosynthesis 
is not essential for bacterial cell viability; however, inhibitors targeting this process may have the 
potential for use in combination therapeutics. Combining antibiotics with agents that are not 
microbicidal when administered alone has been proven to be a successful strategy for the 
treatment of multi-drug-resistant bacterial infections.117 Inhibition of capsule formation may 
unmask patterns on the bacterial cell surface, which are important for pathogen recognition and 
clearance by the innate immune system. Establishment of a robust, validated test system allowed 
for inhibitor screening of compound libraries. To identify inhibitors with moderate affinity (e.g. 
fragment-based screening)132,133 and/or moderate water-solubility, a sensitive assay was required. 
Therefore, we developed a method for the quantitation of the enzymatic reaction products with a 
low detection limit, in order to be able to employ low substrate concentrations around the Km 
value of the enzymes. The developed assay allowed the fast screening of a library of selected 
small molecules as potential inhibitors of CapD and CapE, respectively. Suramin, a drug used for 
the treatment of trypanosome infections,126 showed selective inhibition of CapE with an IC50 
value of 1.82 µM tested at a substrate concentration of 1 mM (Km value of CapE 457 µM). It 
acted as a non-competitive inhibitor with respect to the substrate UDP-D-GlcNAc. Due to its 
relatively high potency and selectivity versus CapE, suramin may be a useful tool for studying 
capsule biosynthetic enzymes. The evaluation of suramin derivatives may yield even more potent 
CapE inhibitors. Although suramin is still therapeutically used to treat tropical infectious 
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diseases, it is not an ideal drug. Its molecular size (1297 g/mol) and high negative charge at 
physiologic pH due to six sulfonate groups hamper peroral bioavailability. Suramin has been 
found to interact with a number of protein targets, including purine P2 receptors,134 
ectonucleotidases,54 G proteins,135 and ribosomes.136 It has been shown to penetrate into cells by 
an active transport mechanism and can even cross the blood-brain barrier.137 Therapeutic plasma 
concentrations of suramin are in the range of 10-50 µM,138 and at the concentrations reached in 
clinical applications, bacterial CapE is likely to be completely inhibited. 
In CapD inhibition studies, we identified the β-lactam antibiotic ampicillin as an inhibitor of 
CapD (IC50 40.1 µM) showing a non-competitive mechanism of enzyme inhibition. The related 
amoxicillin and the ampicillin prodrug pivampicillin were inactive a test concentration of 10 µM, 
while dicloxacillin was similarly potent as ampicillin in the screening assay (Table 6.1). All 
further investigated β-lactams (cefitixime, cefotaxime, cefuroxim, ceftaroline fosamil, oxacillin, 
phenoxymethylpenicilic acid, benzylpenicillin, flucloxacillin, piperacillin, sultamicillin, 
ticarcillin, bacampicillin, cloxacillin, penicillin G, mecillinam, ertapenem, meropenem, 
aztreonam, and potassium clavulanate) did not show any significant inhibition at a test 
concentration of 10 µM. Ampicillin is a perorally bioavailable drug, able to penetrate eukaryotic 
lipid bilayers. Ampicillin also appears to cross the staphylococcal cell membrane. The inhibitory 
concentration of ampicillin at CapD is not much higher than typically observed therapeutic drug 
levels.139 CapD catalytic activity was also inhibited in the presence of the PG precursors UDP-D-
MurNAc-pentapeptide and lipid II. The findings that ampicillin and the structurally analogous D-
Ala-D-Ala dipeptide inhibit CapD activity (Table 6.1) suggest that the C-terminal end of the 
pentapeptide side chain may represent the minimal structure required for inhibition. Moreover it 
is conceivable that the inhibitory effect of ampicillin on capsule production observed in whole 
cells might be of clinical relevance and raises the possibility of additional target sites for β-
lactam antibiotics. 
A novel mechanism for regulation of CP biosynthesis has been approved. In S. aureus, CP 
biosynthesis occurs predominantly in the late-exponential and post-exponential growth phase.140 
Post-translational control of S. aureus capsule expression is exerted by the bacterial tyrosine 
kinase (BY kinase) complex CapAB.141 As deduced from kinase assays, the dehydrogenase 
CapE is an endogenous substrate of CapAB, and phosphorylation of CapE results in enhanced 
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conversion of the precursor UDP-D-GlcNAc in vitro. It could be also demonstrated that the 
synthesis of UDP-D-ManNAcA is regulated by CapAB-mediated tyrosine phosphorylation of the 
dehydrogenase CapO.142 In contrast, no regulatory target of the CapAB complex could be 
identified within the first reaction cascade; neither CapD nor CapN are phosphorylated by 
CapAB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
5 Summary and outlook 
 
This PhD thesis consisted of three projects dealing with enzymes that are of considerable interest 
as novel drug targets. 
 
5.1 Investigation of ecto-5’-nucleotidase as anti-cancer drug target 
 
Ecto-5’-nucleotidase (eN, CD73) catalyzes the hydrolysis of nucleoside monophosphates 
(mainly AMP), yielding the corresponding nucleoside (mainly adenosine) and inorganic 
phosphate. The enzyme has been found to be overexpressed on many cancer cells, and eN-
generated adenosine prevents tumour destruction by inhibiting antitumor immunity. Therefore 
treatment with eN inhibitors may be a promising novel strategy for cancer therapy. In the present 
study we studied nucleotide mimetics synthesized in our group which consist of a nucleoside 
scaffold substituted in the 5’-position with a dipeptide moiety. The compounds were investigated 
at rat eN using a capillary electrophoresis-based assay; identified inhibitors at rat eN were further 
investigated at human eN. 
Several novel nucleotide mimetics have been found to act as pH-dependent eN inhibitors 
showing increased potency at acidic pH values. The most potent compound was AMB552.3a, 
showing a non-competitive mechanism of inhibition (see Figure 5.1). Since tumor tissues 
typically show low extracellular pH values, the new inhibitors might act as tumor-selective eN 
inhibitors without affecting physiologically important functions of eN, such as the production of 
adenosine in blood vessels mediating vasodilatory effects. 
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Figure 5.1. (A) Compound AMB552.3a was found to act as an allosteric enhancer of eN at 
physiologic pH of 7.4. Since low extracellular pH values are a hallmark of cancer,41–45 
AMB552.3a might act as tumor-selective eN inhibitors without affecting physiologically 
important functions of eN, such as the production of adenosine in blood vessels, which shows 
vasodilatory effects.46 (B) Determination of enzyme inhibition mechanism for AMB552.3a at pH 
5.6: AMB552.3a is a non-competitive inhibitor for eN at pH 5.6 (inhibitor concentrations for 
determination were 2 µM, 5 µM, 10 µM and 15 µM). 
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5.2 Investigation of cerebroside sulfotransferase as a target for metachromatic 
leukodystrophy 
 Cerebroside sulfotransferase (CST) is a promising new therapeutic target for the 
treatment of metachromatic leukodystrophy (MLD), a devastating genetic disease. In the 
absence of an effective therapy, MLD leads to early death of the young patients. In the 
present study we developed and validated a test system for the monitoring of the catalytic 
activity of cerebroside sulfotransferase (CST) via quantification of adenosine-3′,5′-
diphosphate (PAP) by capillary electrophoresis (CE). 
 The CE method is sensitive, robust and suitable for CST inhibitor screening, Ki value 
determination, and enzyme kinetic studies. The new assay will be useful for the 
identification and development of novel CST inhibitors which have great potential for the 
treatment of MLD. 
 C16 (N-((2R,3R,4S)-3,4-dihydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)palmitamide) was found 
to be the first competitive inhibitor versus galactocerebroside of CST, with an IC50 value 
340 µM. The new CST inhibitor C16 can be used as a lead structure and be further 
optimized to obtain potent CST inhibitors, which are urgently needed for the treatment of 
MLD. 
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Figure 5.2. Concentration-inhibition curve of the cerebroside sulfotransferase (CST) inhibitor 
C16 (IC50 = 340 µM). 
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5.3 Analysis of the Staphylococcus aureus capsule biosynthesis pathway 
Bacterial polysaccharide capsules are of clinical relevance for most Gram-positive pathogens and 
the biochemistry of the synthesis of this important cell envelope constituent is not fully 
understood. For functional characterisation of the capsule biosynthesis enzymes CapD and CapE, 
a new and robust CE-based method applying micellar electrokinetic chromatography (MEKC) 
was developed. Especially for the purified integral membrane protein CapD, which catalyze the 
first step in the synthesis of the soluble capsule precursor UDP-D-FucNAc, is for the first time 
be functional characterized according to our knowledge. With this newly established method, 
kinetic studies for CapD and CapE enzymes were performed and a compound library was 
screened in search for inhibitors. Besides the identification of a numerous inhibitors, the finding 
that selected beta-lactam antibiotics as well as structurally similar peptidoglycan precursors 
inhibit CapD activity, suggests an integrated mechanism of regulation for cell envelope 
biosynthesis pathways. The inhibitory effect on capsule production observed in whole cells 
might further be of clinical relevance and raises the possibility of additional target sides for β-
lactam antibiotics. 
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Figure 5.3. Concentration-dependent inhibition of CapD and CapE. (A) CapE inhibition by 
suramin (IC50 1.82 ± 0.40 µM); (B) CapD inhibition by ampicillin (IC50 40.1 ± 14.9 µM); (C) 
CapD inhibition by the pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala (IC50 73.9 ± 12.8 µM). 
Substrate concentration was 1 mM. 
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6 Experiments 
6.1 General  
6.1.1 Chemicals 
 
3-(cyclohexylamino)-1-propanesulfonic acid (CAPS) Sigma-Aldrich 
3'-Phosphoadenosine-5'-phosphosulfate (PAPS, 850 µM, 75 µl per 
vial)  Bellbrook Labs, 2059 
adenosine 3′,5′-diphosphate sodium salt (PAP),  Sigma-Aldrich 
adenosine 5′-monophosphate sodium salt (AMP) Sigma-Aldrich 
ATP disodium salt AppliChem, A1348   
boric acid Merck 
calcium chloride dihydrate Fluka, 21097   
calcium chloride, anhydrous AppliChem, A3652   
cerebrosides Matreya LLC 
di-natriumtetraborat 10 Hydrate (Borax) Merck 
disodium hydrogen phosphate, anhydrous AppliChem, A1046   
DMSO (cell culture) AppliChem, A3672   
glucocerebrosides Matreya LLC 
guanosine 5′-diphosphate (GDP) Sigma-Aldrich 
HEPES Roth, 9105.4   
hexadimethrine bromide (polybrene) Sigma-Aldrich 
hydrochloric acid 37% Sigma-Aldrich, 30721   
magnesium chloride Sigma, M8266   
potassium chloride Fluka, 60128   
sodium chloride Roth, 9265.1   
sodium hydroxide Fluka, 71689   
Triton™ X-100 Sigma-Aldrich 
uridine Sigma-Aldrich 
uridine 5’-monophosphate disodium salt (UMP) Sigma-Aldrich 
α-Galactosyl Ceramide (KRN7000)  Avanti Polar Lipids, 867000P 
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6.1.2 Material and instruments 
 
autoclave   VX-95, Systec   
3850 ELV, Systec   
balance, analytical   XA205DU Excellence, Mettler Toledo   
balance, precision   SBC 42, SCALTEC   
440-47N, KERN   
centrifuges   Mikro 200, Hettich   
AllegraTM 21 R, Beckman Coulter   
AvantiTM J-201, Beckman   
Rotofix 32, Hettich   
MilliQ   PURELAB flex, ELGA   
pH-meter   691 pH Meter, Metrohm   
Seven Easy, Mettler Toledo   
pipets   Eppendorf   
vortex mixer   UNIMAG Zx³, UniEquip   
Vortex Genius 3, IKA   
MS2 Minishaker, IKA   
centricon 50 kDa Amicon Ultra, Ultracel – 50K UFC905024, Lot : R9MN42350 
fused-silica capillary Polymicro Technologies 
P/ACE MDQ CE Beckmann 
 
 
 
 
 
 
 
 
 
 
6.1.3 Enzymes preparations 
6.1.3.1  eN 
Recombinant rat eN, which was obtained from Prof. Zimmermann’s group, was expressed in 
insect cells and was purified by affinity chromatography using agarose-coupled GSH as 
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described previously.48  The GPI-anchor was eliminated, and GST was attached to eN to obtain a 
fusion protein. The purity analysis is shown in Figure 6.1: the GST was around 25 kDa, GST-
5NT was around 100 kDa, and BSA was around 70 kDa. 
Recombinant Human eN was obtained from R&D Systems (5795-EN-010).  
 
 
Figure 6.1. eN purity analysis. A: 2500 ng (0.26 mg/ml preparation). B: 5000 ng (0.26 mg/ml 
preparation). C: prestained protein ladder in Tris-glycine (15%). D: 2500 ng (0.49 mg/ml 
preparation). E: BSA 500 ng. F: 5000 ng (0.49 mg/ml preparation)  
 
6.1.3.2 CST 
The human CST enzyme, a Golgi type II membrane protein with maximum activity between pH 
6.5 and 7.0 17,64, was obtained from PD Dr. Matthias Eckhardt’s group (AK Gieselmann), which 
was produced by Dr. Isabell Zech. The concentration for batch D1_V244 was 0.3 mg/ml. For the 
production of soluble CST, they constructed a plasmid which encodes a fusion protein of the 
signal peptide of transin fused to the IgG-binding domain sequence from staphylococcal protein 
A and the lumenal domain of human CST. The signal peptide of transin leads to the secretion of 
the fusion protein and the IgG-binding domain sequence (protein A Tag) enables the purification 
of the protein from the cell culture supernatant. They generated a stably transfected CHO cell 
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line and use the supernatant from the cells for the purification procedure. For the purification 
they use IgG Beads. The protein A-tag of the fusion protein binds to the beads and after washing 
steps the elution is done under acidic conditions. 
 
 
Figure 6.2. CST purity analysis. The determination of CST-concentration with a coonassie-
stained gel by using BSA standards. The concentration of BSA as standard was 0,71 µg/18 µl; 
purified human CST amount was 18 µl. 
 
6.1.3.3 CapD and CapE 
CapD and CapE were obtained from Prof. Sahl’s group, which were produced by Hannah Ulm 
and Marvin Rausch.  
Oligonucleotide primers for amplification of genomic sequences encoding capD (capD_for: 5’-
TATACATATGGCTAGCTTATCTGTGAAATTG-3’; capD_rv: 5’-
TTTGTCTCGAGATAATTATCTCCCTTTTTGC-3’) and pglF (pglF_for: 5´-
GCGCGCATATGCTTGTGGATTTTAAACCTTC-3´; pglF_rv 5´-
GCGCGCTCGAGTTATACACCTTCTTTATTGTGTT-3´) were purchased from Operon 
Technologies (Germany) PCR reactions were carried out using Phusion DNA polymerase (NEB). 
Genomic DNA of S. aureus Newman was used as a template for capD amplification. A truncated 
version of pglF gene (amino acids 130-590) was amplified using genomic DNA from a clinical 
isolate of C. jejuni as a template. PCR products were digested with type II restriction 
endonucleases (NheI/XhoI for capD; NdeI/XhoI for pglF; NEB) and ligated (T4 DNA ligase, 
Roche) with appropriately restricted expression vectors (Novagen). CapD was cloned into 
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pET24a. PglF was cloned into pET28a. The resulting plasmids were confirmed by DNA 
sequencing (Sequiserve, Germany) and used for recombinant expression of hexahistidine-tagged 
fusion proteins. Plasmid pKBK50d used for overexpression of CapE-His6, has been described 
previously 120. Recombinant hexahistidine-tagged fusion CapD (CapD-His6) was expressed in 
host strain E. coli C43 (DE3).93,143 Recombinant hexahistidine-tagged fusion CapE (CapE-His6) 
was expressed in host strain E. coli BL21 (DE3). PglF, which has the same product (UDP-2-
acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose) as CapD, was obtained as a recombinant 
truncated version of the enzyme from C. jejuni, as described by Schoenhofen et al122. 
 
 
 
Figure 6.3. SDS-PAGE analysis of purified recombinant enzymes CapD, PglF and CapE. Protein 
marker: PageRuler Plus Pre-Stained Protein Ladder (10 - 250 kDa); Fermentas.  
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6.2 Operation for capillary electrophoresis 
6.2.1 Strategy for establishing capillary electrophoresis methods  
A simple workflow of CE method for small molecules detection is shown in Figure 6.4. The 
general strategy is summarized as below:  
 
Step 1: Separation of analytes  
The analytes that need to be separated are substrate and product of a certain enzyme (enzyme 
cofactors should be also considered). One can separate them based on their charge or size 
differences. Charge differences can be predicted by software Marvin (ChemAxon). When the 
analyte has a good chromophore (e.g. aromatic rings), DAD detector can be used. Usually the 
best separation will be achieved in a buffer pH nearby the pKa value of analytes. A basic 
capillary zone electrophoresis mode can be chosen as the starting point. 
 
Step 2: Quantification of analytes – stacking   
In order to maximize the sensitivity of detection for enzyme product, one can examine the 
product property and apply suitable stacking method. 
 
Step 3: Internal standard (I.S.) 
Internal standard is necessary for the method validation. A good internal stand should: 
 Have no interaction with the other assay components. 
 Have a good separation from the other analytes. 
 Have a quick migration time.  
 
Step 4: Method optimization – other parameters 
All CE method parameters (including injection time, separation voltage, capillary length, etc.) 
can be further optimized, in order to achieve a fast and clean separation.  
 
Step 5: Sample preparation 
The sample must be homogenized and deproteinized before CE injection.  
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Step 6: Validation 
Before the inhibitor screening or the enzyme kinetic characterization, a validation step is 
required. 
 
Step 7: Application 
After optimization and validation, the new CE method is ready for application. Usually a good 
CE analysis method should be simple, fast, cheap and sensitive: 
 Simple: the analytes should be consumed as less as possible, and the sample preparation 
steps should be kept as simple as possible. For example, there are many ways to stop the 
enzyme reaction:  by heating, by adding organic solvent, or by filtering. If the analytes 
are stable under heating, the heating method is usually preferred.  
 Fast: the migration of analytes should be as quick as possible. For example, to reduce 
migration time by increasing the separation voltage, by using shorter capillary, or by 
changing the buffer pH value.  
 Cheap: it would be good to find a cheaper way to carry out the assay. For example, a low 
LOQ method consumes less enzyme, and a good dynamic coating is cheaper than coated 
capillary. 
 Sensitive (Low LOQ): sample stacking is the most useful way to achieve a lower LOQ. 
 
Step 8: To monitor new enzyme catalyze activity 
First of all, we keep the enzyme incubation time within the steady-state. The next step is to make 
sure that the enzyme reaction can be stopped completely, and meanwhile to check the substrate 
degradation under the experimental condition (e.g. by 99°C heating). Last but not the least is to 
check other noises in this assay, because it is possible to observe an apparent reaction in the 
absence of enzyme substrate. (Because enzymatic activities may be contained in the water by the 
presence of bacteria, or additional substrate may come from the endogenous substrate in the 
crude tissue preparation, or chemical hydrolysis may occur). In order to detect noises, we need a 
blank control, which contains inactive enzyme, and the blank rate must be subtracted from the 
apparent rate. 
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6.2.2 Capillary electrophoresis working process 
1. Prepare samples and buffers 
We use three trays inside the CE instrument: BI, BO, and SI. 
 BI: buffer inlet tray for 2.0 ml vials 
 BO: butter outlet tray for 2.0 ml vials 
 SI: Sample inlet tray for 0.5 ml vials or PCR vials 
 
The picture below shows that the capillary can stay in position BI: A1 and BO: A1 
Determine optimum wavelength 
Select appropriate mode, buffer type, 
and buffer pH 
Determine optimum voltage and select 
capillary temperature 
Improve resolution 
Optimize sampling volume 
Usually 200, 214 or 260 nm for small molecules 
Neutral analyte: Borate (plus SDS) with pH 6-10 
Charged analyte: Phosphate (plus Polybrene) with pH 2-8 
To start with short capillary (e.g. 40 cm), and a longer 
capillary can be used to improve resolution. 
Try sample stacking when the analyte peak is small. 
When we increase the voltage, we can 
decrease the temperature. 
Method development Explanation 
Figure 6.4. Simple workflow for CE method development 
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Every time when you turn on the instrument, it needs a few minutes for configuration. Don’t 
open its cover until the light is ready and the capillary is in the home position (usually BI: A1 
and BO: A1) 
 
 
 
The 2.0 ml glass vial is for the buffer tray. As shown below: 
 The vial should be straight. If it is not straight, don’t use it. 
 Wrap paper outside the vial to fix the vial in the buffer tray. 
 Wash the vial with water after using and dry it before the next use. 
 Fill the buffer to the red line. 
 Before you load the vial, make sure the cap fits the bottle and no buffer is outside the 
bottle. If the cap is not fit or dirty, don’t use it. If there is buffer outside, please dry it first. 
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The PCR vial is for sample tray. As shown below: 
 Wash the vial only with Millipore water after using and dry it before the next use. 
 Make sure there are no bubbles inside the sample. 
 Before you load the vial, make sure the cap fits the bottle and no buffer outside the bottle. 
If the cap is not fit or dirty, don’t use it. If there is buffer outside, please dry it first. 
 
 
 
 
 
2. Run sequence or single run 
2.1 single run 
As shown below, when you click the single run button, you can open the dialog window and then 
set your run: 
 Method path: where you load your method 
 Data path: where you save your result 
 File name: the name of your result 
 Sample inject: the sample position 
 Description: detail information about your assay 
 Number of run: you can repeat your measurement 
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2.2 Sequence (multiple runs) 
As shown below, you can open the sequence window and write your sequence: 
 Method: load your method 
 File name: the name of your result 
 Sample inject inlet: the sample position 
 Description: detail information about your assay 
 Reps: you can repeat your measurement 
 Sample Injection Duration: it can be overwrite, but usually you don’t need to change it 
Then you save method and sequence, and click the run sequence button. 
Notice: if you open a sequence from project A, then the data will be stored under project A too, 
no matter which project you log in with.  
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3. Writing methods 
 
Method wizard -> New 
 
 
 
3.1 initial condition 
As shown below: This window shows the initial condition. For the Auxiliary data channels, if 
you choose the Voltage or Current, you will have a window to monitor how it changes. Please 
save the method after your change. 
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3.2 PDA detector condition (For DAD detector) 
Please pay attention to the Electropherogram channel data. Please choose the window with the 
wavelength that you want. Then save method. 
 
 
 
3.3 Time program 
Click Event to write your method: 
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 Rinse 
 Inject 
 Separate 
 End 
 
 
 
Rinse stage: 
 Pressure Type: Pressure or Vacuum. Usually we use pressure. Then give pressure value 
and duration. 
 Tray positions: Choose the inlet (rinse buffer) and outlet (waste) 
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Inject stage 
 Injection Type: Voltage, Pressure or Vacuum. Usually we use pressure and voltage (not 
for neutral solute). Then give value and duration. 
 Tray positions: Choose the inlet (sample) and outlet  
 Allow override: Usually we allow this part to be overridden. 
 
 
 
Separation: 
 Separation Type: Voltage, Current, Power, Pressure or Vacuum. Usually we use pressure, 
current and voltage. The one you choose will be a constant during the separation. Then 
give value and duration. 
 Ramp time: usually it is 0.5 min 
 Tray positions: Choose the inlet (separation buffer) and outlet (separation buffer) 
 Polarity: When you use FS capillary, it is Normal. When you use coated capillary, it can 
be Normal or Reverse. 
 At time: choose at time 0.00 min 
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An example: 
 
 
4. Data analysis 
 
4.1 open data: 
 
 
 
Method->From Results: In the Options section, if you choose From Result, you can check the 
method within this source data. You can choose it when you are in the offline mode. But if you 
analysis data by using online mode, better don’t choose it.  
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4.2 mixed view: 
 
 
4.3 save standard spectrum in library: if you find a good spectrum you can save it and use it for 
identification in future. 
Utilities->Save trace->click the spectrum and save it 
               
 
4.4 Add trace from the library: you can use a standard spectrum in the library for comparison and 
identification with your own result. 
Add Trace…->Open Spectrum File… 
 
4.5 Custom reports 
 
4.5.1 Define peaks 
 
 Open the window with a certain wave length. For example: PDA-260nm.  
 Select MAN PEAK and click before and after the peak you  ANALYSE 
 If more peaks than you want are identified, select INT OFF and select the  ANALYSE  
 DEFINE PEAK: select range  Replace existing peaks in table and click OK 
 If you want to further change your defined peak range, just click modify button. 
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4.5.2 Generate report 
 
Select PEAK/GROUP TABLES and rename each peak appropriately  ANALYSES 
 
 
 
 
Select EDIT CUSTOM REPORT, and then load your own template. You should choose the 
wave length that you analysis under the property option, for example: PDA-260nm. Otherwise 
you could not have the right result. 
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Print it out with a printer or a PDF printer. Use corrected peak area for calculations. You may 
need Excel or Prism for further analysis.  
5. Other aspects 
5.1 Calibrating the PDA Detector 
Calibration should be made again when the following experiment conditions changed: 
 Internal standard (I.S.): if a new I.S. is purchased (e.g. different batch) or a new 
concentration is used, the calibration should be updated. 
 Injection method (including capillary length): different injection way or amount will change 
the injected plug length or ion proportion, which can affect the resolution 
 Capillary batch: the quality of different capillary batch can change, which will affect the 
resolution. 
 D2 lamp is changed. 
 
Calibrate the PDA detector as below: 
To open calibration window by choosing: Control->Diagnostics->Calibrate 
To turn on Hg light by choosing: Diagnostic Graphs->Hg Transmission Spectrum 
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After the Hg Lamp On (as shown above), click right mouse button and choose: Calibration 
 
5.2 The corr. area calculation setting 
Method->Advanced->Capillary/performance 
To choose the right length parameters is important for the corr.area calculation. 
The USP standard is OK. 
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6.2.3 Maintenance Procedures 
 
1. Capillary cartridge rebuilds 
 
1.1 Remove the old parts: 
 Remove two of the seal-retainer clips from the capillary cartridge. 
 Remove the aperture by pushing from the front of the cartridge and pulling out from the 
back. Make sure the O-ring is removed.  
 Pull the capillary out of the cartridge. 
 If the capillary length needs to be changed, the coolant tubing also needs to be changed. 
Loosen and remove the tubing nuts. Select the desired coolant tubing from the Cartridge 
Tubing Kit .Insert the coolant tubing in the cartridge inlet and press it firmly into the 
cartridge base. 
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1.2 Prepare a capillary: 
 
 Mark the capillary window position. 
 
 Using the capillary cleaving stone. Pull capillary straight off without bending. Do not 
saw back and forth with the cleaving stone. Be sure to wear safety glasses when 
cleaving and breaking the capillary. Use a fire to burn the window, but not that wide. 
Then clean the window with alcohol carefully. 
 Carefully push and twist the capillary through the cartridge until it appears at the 
cartridge inlet. Continue by pulling the capillary through the cartridge until the capillary 
window appears in the cartridge window  
 From the back side of the cartridge, place the aperture and from the front side of the 
cartridge, place the retainer O-ring by using the O-ring insertion tool. 
 Carefully insert the capillary Seal Retainer Clips over the capillary at each end and press 
to snap in place. 
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 At the cartridge inlet, carefully push the capillary into the cartridge until the capillary 
stops against the wall of the coolant tubing.  
 Holding the capillary against the template, cut off additional length. 
 Insert the new cartridge. Then clean it before the first use: 15min, 20psi with NaOH, then 
15min, 20psi with buffer, at last 15min separation with buffer (until the baseline is flat). 
For coated capillary, use Millipore water instead of NaOH, and increase pressure to 50psi. 
 
! Seal it, without coolant leakage. 
! Do it carefully, to prevent capillary damage. 
! There should be a cartridge inside the CE when you turn on the instrument, otherwise the 
coolant will go out. 
 
The most important thing is: electrode should be longer than the capillary. The length difference 
between electrode and capillary depends on the injection way: 
 Hydrodynamics injection: 1 mm 
 Electrodynamics injection: 2-3 mm 
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The way to break the capillary: 
Pulling while breaking. 
 
2. Instrument care 
The most important thing for CE is to clean it! Especially for the interface block part, when you 
work with gel, cleaning is the first step for every day’s work. To be CE expert is the second 
important thing for CE user. 
The following 4 parts should be cleaned weekly with water and ethanol: electrodes, holders, area 
below sample track and sample track. 
 
 
 
 
 
2.1 Before you begin, you will need: 
• VE water 
• Paper 
2.2 All surfaces that come into contact with samples must be treated. 
 Lift the cartridge cover door at the front of the P/ACE MDQ. 
 Turn the system power off. 
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 Remove the capillary cartridge and buffer/sample trays as required to clean all internal 
surface areas. Clean each surface at least two times and allow the instrument to dry 
completely. 
 Clean all external instrument surface areas thoroughly, at least two times and allow the 
instrument to dry completely. 
 
 
2.3 Cleaning the Interface Block, Ejectors and Electrodes 
 Lift the cartridge cover door. 
 Loosen the two thumb screws and lift the insertion bar. 
 Remove the capillary cartridge from the interface block. 
 Remove the ejector covers and ejectors for cleaning  
 Using cotton swabs, clean interface block, electrodes and ejector surfaces with VE water 
followed by methanol, and then let it dry. 
 Reinstall the capillary cartridge in the interface block. 
 Lower the insertion bar and tighten the two thumb screws. 
 Close the cartridge cover door. 
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3. Change modular 
UV or PDA Detector/Capillary Cartridge Installations: 
3.1 Before you begin, you will need: 
 • UV or PDA Detector 
 • Fiber optic cable (UV cable is 2 ended and the PDA cable is 3 ended) 
3.2 Proceed as follows: 
 Verify that power is off and no capillary cartridge is installed. 
 Lift the cartridge cover door and find the detector mounting location as shown below: UV 
detector is the left one and PDA detector is the right one. 
 Position the detector on the mounting location. Carefully slide the detector back to make 
contact with the back-plane receptacle. 
 Tighten the thumb screw until snug. 
 Unpack the fiber optic cable and remove the protective covers from each end. Be sure to 
keep the protective covers for storage when not in use. Connect the cable to the clamp 
arm first, then to the detector. The remaining end of the fiber optic cable will be 
connected after completing the capillary cartridge installation. 
 Connecting the fiber optic cable in the reverse order may cause damage to the fiber. 
 
Inside the DAD detector, position 8 is for the PDA detector, which is always empty; while 
position 1 is for auto zero. When the capillary window is broken, clean this part and fibre 
head with water and wait until dry.  
 
 
115 
 
 
 
 
 
 
 
8
1
 
 
116 
LIF Detector Installation: 
3.3 Pre-installation Requirements and overview 
 Initial installation, which will be done by a Beckman Coulter Field Service Engineer, 
includes setting up the laser, connecting it to the LIF Detector System, and verifying 
proper system operation (including operation of the laser interlock system, which 
prevents the user from exposure to laser light). The LIF Detector requires software and 
instrument firmware version 4.0 or higher for 32 Karat Software. 
 If installed, remove the UV or PDA detector from the upper-right corner of the P/ACE 
MDQ instrument. Install the Interconnect Module in the upper-right corner. Secure the 
module by finger tightening the locking screw located in the front lower middle area of 
this module. 
 Pull back the interlock cover, hold the cable securely, and screw the fastener into the 
Interconnect Module. Do not to allow either cable to become twisted during installation 
to avoid damaging the fiber optic line inside the cable. Finally, install the interlock cover. 
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NOTE: The black cables are optical cables. Therefore, you have to be careful with these cables 
because they break very easily. 
 
We have two laser generators, lacer A is from Beckmann (left side), which has 488 nm excitation 
wave length and 520 nm emission wave length. Lacer B is from another company (right side). 
The connection tip of Beckmann’s lacer fibre is smaller than lacer B’s (as shown below), while 
lacer B’s connection tip is too big to connect to the laser detector. If we want to use lacer B, the 
first step is to use a needle to enlarge the lacer module’s connection hole. 
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The lacer detector in our lab only has channel one, which means we only have one lacer 
channel. 
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When people install the lacer cartridge, they should check the spring. It can be pressed up 
and down: 
 
 
Settings for software: 
 Only channel 1, no channel 2 
 Normal: 16-25 
 Excitation 488 nm 
 Emission 520 nm 
 4Hz 
 
 
Laser 1 
Insert the Laser Interconnect Module into CE instrument. The laser is connected to instrument by 
two cables 
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Laser 1 
 
 
Laser Interconnect Module 
 
Laser 2 
The laser has to be connected via a Remote Box to CE instrument. There have to be one cable 
between remote box and laser and one between remote box and CE instrument. The laser can not 
be switched off at the CE instrument, and it has to be done at the laser directly. 
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Laser 2 
 
Remote Box 
 
3.5 Preparing the Cartridge for LIF Usage 
The LIF Detector uses a special plug, which is not interchangeable with those used on the 
UV/PDA system. 
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6.2.4 Solutions for some problems 
1. Coolant low 
Usually there is a leakage somewhere from the cartridge: 
 The connections ->reconnect it, or change new connection 
 The tube -> when you change a new tube, make sure the O ring is inside and you seal it 
well 
 The cartridge ->change cartridge, but it is expensive 
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2. PDA light low 
If the light is OK, then the detection window has problems: 
 The window is dirty ->preparing the capillary window carefully without contamination. 
But if it is dirty already, you have to prepare a new one. 
 Forgot calibration ->calibrate it after changing a new capillary 
 The aperture is not fit. ->usually the 800 aperture is right size. Otherwise you have to 
enlarge the window a little bit. The 200 aperture is for UV detector. 
 
3. No current 
 Current too high -> decrease the voltage or decrease the concentration of separation 
buffer. 
 Bubble inside ->If it comes from the sample, add additional 10psi pressure with the 
voltage during the separation. Or lower the current, maybe too hot. 
 
4. Current leakage 
 The capillary is broken, usually the window part -> change new capillary 
 The insides of CE are too wet or dirty -> clean the inside of CE and dry it. 
 
5. No peak 
 Maybe injection failure -> adjust the injection type, magnitude and lasting time 
 Maybe the electron nods are dirty or damaged -> if it is dirty, clean them with ethanol 
and water; if it is bend, make it straight again carefully 
 Maybe the capillary inner wall is damaged  -> change a new capillary 
 
6. Broken light 
When the light is broken, the baseline will be not flat, as shown below: 
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7. Contaminated buffer bottles 
We encountered a migration time delay problem, which caused by dirty running buffer bottles 
and caps. The contamination was caused by Polybrene, which was used in dynamic coating 
method. In this case, by using dirty buffer bottles in the normal CZE mode, an extra coating 
effect was induced. To avoid this trouble occurs in future, we can separate the buffer bottles and 
caps according to different methods, and we need to use ethanol for additional cleaning step in 
order to remove polybrene.   
The basic but most important aspects of separation buffers of CE are pure reagents and clean 
Millipore water. Moreover, the separation buffer bottles should be clean and buffer should be 
degassed before use.  
 
8. Broken capillary detection window  
In the very beginning the detection window was broken, so the buffer contaminated the inside of 
CE (including optical fibre, part of the surface of the modular, aperture and O-ring) 
Before cleaning the electropherogram has baseline with curve shape, shown as below (this is 
sample with 5NT reaction mixture 100 µL and Uridine 100 µL): 
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After cleaning the optical fibre (first water, then ethanol), the baseline looked better as below: 
6.  
 
After the second cleaning of the optical fibre (first water, then ethanol) and part of the surface 
of the modular which attached to the detection window (only water), the detection has been 
improved as below: 
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After the third cleaning of the optical fibre and change clean aperture and O-ring, the baseline 
totally recovered: 
 
 
6.2.5 Important practical aspects 
1. Capillary 
To prepare for the CE, the capillary should be cut to the appropriate length with a ceramic knife, 
so that the ends of capillary is flat and square. This is especially important for the inlet end of the 
capillary, because it can influence the sample injection. A window is created closer to the outlet 
end, which ideally be approximately 0.3 cm in length. The normal FS capillary window can be 
prepared by burning with a flame and then wiping with an tissue with ethanol. The coated 
capillary window can be prepared by placing a drop of strong acid on it and then touching the 
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acid drop with a hot soldering iron. Before placing the capillary into a cartridge, clean it overall 
with a tissue with ethanol. When using a new capillary or change to a new buffer, the first step is 
conditioning, which is important for stable migration time, good baseline, and acceptable 
reproducibility.   
2. Buffer 
The basic but most important aspects of separation buffers of CE are pure reagents and clean 
Millipore water. Moreover, the separation buffer bottles should be clean and ice cold buffer 
should be degassed before use. Borax buffer has two advantages: It forms complex with cis-diols, 
which imparts an additional negative charge to the analyte. It generates less Joule heat than 
phosphate buffer. 
 
3. Joule heat  
To increase the voltage or buffer concentration may increase the sharpness of the peaks and 
improve resolution. However, the Joule heat is also be increased, which results in bad resolution 
and analyte stability or even detection window damage. 
 
4. Conditioning 
Pre-conditioning of the new capillary is quite important for this method. The graph below shows 
the baseline differences: A. after 100 minutes pre-conditioning, the baseline is flat; B. after 20 
minutes pre-conditioning, the baseline is not so flat. 
 
 
 
 
 
A: After 100 min pre-conditioning B: After 20 min pre-conditioning 
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6.3 Investigation of ecto-5’-nucleotidase as anti-cancer drug target  
6.3.1 Capillary electrophoresis set up 
All experiments were carried out by using a P/ACE MDQ capillary electrophoresis system 
(Beckman Instruments, Fullerton, CA, USA) equipped with a DAD detection system. Data 
collection and corrected peak area analysis were performed by 32 Karat software obtained from 
Beckman coulter (Fullerton, CA, USA). The capillary temperature was kept constant at 25°C. 
The electrophoretic separations were carried out by using uncoated fused-silica capillaries of 40 
cm total length (30 cm effective length) × 75.5 µm (id) ×363.7 µm (od) obtained from Polymicro 
Technologies (Kehl, Germany). The following conditions were applied: λmax = 260 nm, 
acquisition rate 4 Hz, separation voltage = 20 kV, running buffer 40 mM borax buffer, pH 9.1, 
hydrodynamic injection (0.5 psi, 5 sec). The capillary was washed with 0.1 N NaOH aq. for 2 
min (20 psi) and with running buffer 2 min (20 psi) before each injection. The test mixture was 
prepared with 100 µl sample and 100 µl internal standard (I.S.). The internal standard was 12.5 
µM uridine dissolved in autoclaved Millipore water. 100 µl test mixture was pipetted to the 
sample vial and subsequently measured by CE. Further data analysis were carried out by 
software Graph Pad Prism 4 (Graph Pad Software, Inc. California) and Excel.  
 
  Capillary conditioning method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 10:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 10:00 min BI:C1 BO:B1 Forward 
0:00 Separate – voltage 15 kV 30:00 min BI:A1 BO:A1 0.5 min ramp 
30:00 End      
  Sample analyzing method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 2:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 2:00 min BI:C1 BO:B1 Forward 
 Inject – pressure 0.5 psi 5 sec SI:A1 BO:A1 override, forward 
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0:00 Separate – voltage 20 kV 5:00 min BI:A1 BO:A1 0.5 min ramp 
5:00 End      
BI: A1 – Separation buffer (Separation); BI: B1 – NaOH (Rinse); BI: C1 – Separation buffer 
(Rinse); BO: A1 – Separation buffer (Separation); BO: B1 – Waste 
 
6.3.2 Assay description 
6.3.2.1     Buffer preparation 
Running buffer (40 mM borax, pH 9.1) was prepared as below: 
Put 3.051g borax (Na2B4O7·10H2O) and 200 ml Millipore water in 400ml beaker, add 16.7 ml 
400 mM boric acid to adjust the pH value from 9.30 to 9.10, then to use ultrasonic bath for 5 min. 
The current of CE should be around 150 µA by using this buffer (with separate voltage 20 kV).  
The components of enzyme reaction buffer were investigated, in order to figure out in which 
buffer can enzyme eN display maximum activity (Vmax) (Table 6.1). The enzyme reaction buffer 
contained 20 mM HEPES, 140 mM NaCl, 1 mM MgCl2, and 1 mM CaCl2 has been chosen. 
Buffer pH values were pH 7.4, pH 5.6, and pH 4.9, which were adjusted at 37°C with NaOH. 
 
Table 6.1. Comparation of Vmax value of eN in different reaction buffers 
  
buffer 
Km (µM) Vmax 
(µmol/min/mg 
protein) 
date 
 
1 
Hepes 20 mM, NaCl 140 mM, CaCl2 1 
mM, MgCl2 1 mM, pH 5.6 
 
155 ± 23 
 
0.917 ± 0.116 
March 
2010 
 
2 
Hepes 20 mM, NaCl 140 mM, CaCl2 1 
mM, MgCl2 1 mM, pH 7.4 
 
110 ± 21 
 
1.5 ± 0.3 
March 
2010 
 
3 
Hepes 20 mM, NaCl 140 mM, KCl 5 
mM, CaCl2 1 mM, MgCl2 1 mM, pH 7.4, 
with 1% DMSO 
 
63.6 ± 3.5 
 
0.942 ± 0.053 
January
2010 
 
4 
Hepes 20 mM, NaCl 140 mM, KCl 5 
mM, CaCl2 1 mM, MgCl2 1 mM, pH 7.4 
 
70.38 
 
0.9735 
January
2010 
 
5 
Hepes 20 mM, CaCl2 1 mM, MgCl2 1 
mM, pH 7.4, with 1%DMSO 
 
65.6 ± 17.1
 
0.726 ± 0.120 
January
2010 
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6.3.2.2     Calibration and validation  
The linearity of the quantitative determination and the limits of detection (LOD) and 
quantification (LOQ) of the enzymatic product adenosine were determined by processing five-
point calibration curves (triplicate samples with duplicate measurements) in the presence of 6.25 
µM uridine as I.S. The precision and accuracy values were determined at the following 
concentrations (triplicate samples with duplicate measurements): 5, 10, 20 and 40 µM. Accuracy 
was determined by calculating the ratios of the predicted concentrations and the spiked values, 
and relative standard deviations were calculated. 
If the adenosine concentration is lower than LOQ, the calculation will be not accurate. For 
example, if the LDQ for adenosine is 19 µM, so the final concentration of adenosine in the 
reaction vial should be higher than 19 µM. Especially for the Km value detection: if the 
concentration of substrate AMP is lower than 20 µM, the result will be not trustable, which 
indicates that the requiremnt of LOQ depends on the testing target: LOQ should be at least 10 
folds lower than your target’s Km value.    
The method for calibration is described as below: 
Choose 5 or more concentrations of adenosine, and the lowest concentration should be as low as 
possible. Prepare the right concentrations of adenosine in a 100 µl final volume, than add 100 µl 
I.S. to it. After measurement, divide the adenosine’s corrected area by I.S. corrected area then 
multiply with 100. Create a scatter plot with relative corrected peak area as y axis and substrate 
concentration as x axis. Use the linear regression to generate slope, yx=0, and Sy,x. 
Partial validation is necessary when some parameters in the system are changed (e.g. when the 
batch of capillary is changed). For partial validation of the bioanalytical method, accuracy should 
be determined using a minimum of five determinations per concentration level. The mean value 
should be within ±15% of the theoretical value. At minimum, three concentrations representing 
the entire range of the standard curve should be studied: one with 3 times of LOQ, one near the 
centre, and one near the upper boundary of the standard curve. 
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6.3.2.3     Enzyme catalytic reaction 
Reactions were initiated by the addition of eN. 3.8*10-12 mol eN per vial was consumed for pH 
7.4 reaction buffer assay, and 14*10-12 mol eN per vial was consumed for pH 5.6 and pH 4.9 
reaction buffer assay.  The reaction vials were incubated at 37°C for 15 min. All enzymatic 
reactions were quenched by heating (5 min, 99°C). 
Determination of kinetic parameters for eN. To determine the kinetic parameters (Km and Vmax), 
8 different substrate concentrations were chosen. Each analysis was repeated three times in 
independent experiments.  
Investigation of eN inhibitors. A group of selected compounds were initially screened at high 
concentrations of 100 µM. Subsequently, full concentration-inhibition curves were determined 
for the most potent inhibitors, and IC50 values were calculated. The substrate (AMP) 
concentration for eN inhibition testing was 500 µM, and substrate conversion was strictly 
controlled to be below 10%. The IC50 values of inhibitors were obtained by testing a suitable 
range of inhibitor concentrations (8 data points). The incubation time was 15 min. Negative 
controls were performed in the presence of heat-inactivated enzyme (5 min, 99°C). Each analysis 
was repeated three times in independent experiments. For the determination of the inhibition 
mechanism, 8 different substrate concentrations and 3 different inhibitor concentrations were 
used, and each analysis was carried out with duplicate measurements. 
 
6.3.3 Compound preparation and selection 
 
Table 6.2. The predicted pKa values of pH-dependent inhibitors by the software MarvinSketch. 
 
No. code  Microspecies 
distrabution % 
(ion charge) 
pH5.6 
Microspecies 
distrabution % 
(ion charge) 
pH7.4 
1 
 
 
 
 
AMB 
193 
O
-5,73
N NH
11,58N
H
14,62
HO
13,64,-3,46
OH
12,56,-4,58
O
-7,21
O
O
-7,98
H
N
15,19
O
-1,14
HO
3,43
O
O
OH
5,48
 
 
 
 
56,56(-2) 
43,15(-1) 
 
 
 
98,80(-2) 
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2 AMB 547 
O
-5,74
N NH
9,70N
H
14,23
H
N
12,35
HO
13,57,-3,46
OH
12,96,-4,58
O
-8,79
O
O
-5
O
-6,85
O
-6,40
O
CH3
O
O
-7,33
H3C
 
 
 
 
 
 
99,99(0) 
 
 
 
 
 
99,50(0) 
3 AMB 547H 
O
-5,74
N NH
9,70N
H
14,35
H
N
12,96
HO
13,70,-3,46
OH
12,43,-4,58
O
-8,78
O
O -5,27
O
-6,52
O
-7,12
O
CH3
HO
3,69
O
 
 
 
 
 
98,77(-1) 
 
 
 
 
 
99,48(-1) 
 
4 AMB 548 
O
-5,77
N NH
9,70N
H
14,18
H
N
14,81
HO
13,56,-3,46
OH
12,53,-4,58
O
-9,09
O
O
-5,34
O
-4,84
O
S
H3C
O
-7,69
 
 
 
 
99,99(0) 
 
 
 
99,50(0) 
5 AMB 548H 
O-5,77
N NH
9,70N
H
14,30
H
N
15,01
HO
13,58,-3,46
OH
12,54,-4,58
O
-9,07
O
O -5,34
O
-4,84
HO
3,54
S
O
 
 
 
 
 
99,12(-1) 
 
 
 
 
 
99,49(-1) 
 
6 AMB 563.1 
O
-5,77
N NH
9,70N
H
14,08
H
N
14,76
HO
13,52,-3,46
OH
12,53,-4,58
O
-9,10
O
O
-5,34
O
-4,84
O
O
-7,04
18,26
O
-7,82
O
 
 
 
 
 
99,99(0) 
 
 
 
 
99,50(0) 
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7 AMB 563.1H 
O-5,77
N NH
9,70N
H
14,15
H
N
14,91
HO
13,54,-3,46
OH
12,53,-4,58
O-9,07
O
O -5,34
O
-4,84
HO
3,12
O
O
OH
5,04
 
 
 
 
 
78,53(-2) 
21,40(-1) 
 
 
 
 
 
99,08(-2) 
 
8 AMB 565.1 
O-5,77
N NH
11,58N
H
14,17
H
N
14,91
HO
13,55,-3,46
OH
12,55,-4,58
O-9,10
O
O -7,87
O
-4,84
HO
3,12
O
O
OH
5,04
 
 
 
 
 
78,53(-2) 
21,40(-1) 
 
 
 
 
99,56(-2) 
 
9 AMB 564 
O
-5,74
N NH
9,70N
H
14,42
HO
13,61,-3,46
OH
12,54,-4,58
O
-7,22
O
O
-5,27
H
N
14,92
O
-1,14
O
O
-6,77
18,26
O
O
-7,75
 
 
 
 
 
99,99(0) 
 
 
 
 
99,50(0) 
10 AMB 564.1H 
O-5,74
N NH
9,70N
H
14,60
HO
13,64,-3,46
OH
12,54,-4,58
O
-7,22
O
O -5,27
H
N
15,19
O
-1,14
HO
3,43
O
OH
5,48
O
 
 
 
56,56(-2) 
43,15(-1) 
 
 
 
98,32(-2) 
 
 
11 AMB 566.1 
O-5,73
N NH
11,58N
H
14,62
HO
13,64,-3,46
OH
12,56,-4,58
O-7,21
O
O
-7,98
H
N
15,19
O
-1,14
HO
3,43
O
OH
5,48
O
 
 
 
 
 
56,56(-2) 
43,15(-1) 
 
 
 
 
 
98,80(-2) 
 
 
 
134 
12 AMB 553.1 
O
-5,74
N NH
9,60N
H
14,18
HO
13,66,-3,46
OH
12,42,-4,58
O
-8,78
O
O
-5,27
H
N
12,94
O
-6,70S
O
O
H2N10,27
 
 
 
 
 
99,99(0) 
 
 
 
 
99,37(0) 
13 
AMB 
560.1 
final 
O-5,77
N NH
9,54N
H
14,29
HO
13,58,-3,46
OH
12,54,-4,58
O-9,07
O
O -5,34
H
N
14,97
O
-4,84
HO
3,30
HS
10,05,-9,68
O
 
 
 
 
 
99,50(-1) 
 
 
 
 
 
99,27(-1) 
 
14 AMB 552.3a 
O-5,79
N NH
9,70N
H
14,50
HO
13,63,-3,46
OH
12,54,-4,58
O-7,60
O
O -5,38
H
N
14,92
N
9,03
OHO
1,32
O
HO2,56 O
-4,96
 
 
 
 
99,87(-2) 
 
 
 
 
2,30(-3) 
97,69(-2) 
 
15 ATP  
 
 
73.38(-3)  
24.25(-2) 
 
 
66.53(-4)  
33.30(-3) 
16 AOPCP 
 
 
 
73.91(-2) 
25.55(-1) 
 
 
 
15.30(-3) 
84.24(-2)   
0.46(-1) 
17 AMP 
 
 
 
25,73(-2) 
57,52(-1) 
16,73(0) 
 
 
 
 
 
96,56(-2) 
3,42 (-1) 
0,02 (0) 
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18 Gly 
 
 
 
 
 
 
 
99,93 (0) 
 
 
 
 
98,57 (0) 
19 Asp 
 
 
 
 
 
24,59 (0) 
75,38(-1) 
 
 
 
0,51 (0) 
98,88(-1) 
20 Glu 
 
 
 
 
 
 
95,51(-1) 
 
 
 
99,20(-1) 
 
Firstly I prepared 10 mM stock solution in pure DMSO for every AMB compound. 
Afterwards in order to achieve a higher concentration in my assay, I prepared 10 mM stock 
solution in water for AMB563H, AMB565, AMB566, and AMB193. Actually, it is better to 
prepare all compounds in water when possible. By adding a few drops of NaOH can improve 
the AMB compound’s solubility. 
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Table 6.3. POMs 
Compound code Molecular formula Molecular weight 
[g/mol] 
Inhibitor 
screening* 
inhi% at 100 µM
NaPW12 Na3[PW12O40] x 7 H2O 
 
3074 -1.86% 
NaP5W30 
 
Na15[P5W30O110] x 30 H2O 
 
8320 11.1% 
NaP6W18 
 
Na20[P6W18O79] x 37 H2O 
 
5888 -17.5% 
NaP8W48 
 
Na33H7[P8W48O184] x 92 H2O 14446 47.6% 
NaOP8W12 
 
Na16[(O3POPO3)4W12O36] x 38 H2O 
 
4532 -23.1% 
NaCP8W12 
 
Na16[(O3PCH2PO3)4W12O36] x 16 H2O
 
4128 -59.4% 
KB 1 K4[(Re6S8)(OH)6] 1632 74.5% 
KB 2 K4[(Re6Se8)(OH)6] 2007 67.8% 
KB 3 K4[Re6 S8(CH3COO)6] 
 
1938 19.7% 
KB 4 K4[(Re6S8)(HCOO)6] 1854 89.2% 
*concentration of substrate AMP: 500 µM, Km: 45 µM 
 
 
6.4 Investigation of cerebroside sulfotransferase as therapy target for 
metachromatic leukodystrophy 
6.4.1 Capillary electrophoresis set up 
All experiments were carried out by using a P/ACE MDQ capillary electrophoresis system 
(Beckman Instruments, Fullerton, CA, USA) equipped with a DAD detection system. The 
capillary temperature was kept constant at 15 °C. The electrophoretic separations were carried 
out by using fused-silica capillary of 60 cm total length (50 cm effective length) × 75.5 µm (id) × 
363.7 µm (od) obtained from Optronis GmbH. The following conditions were applied: λmax = 
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260 nm, voltage = -15 kV, running buffer 75 mM phosphate buffer, 0.002% polybrene, pH 5.6 
(adjusted by phosphoric acid), electrokinetic injection (-10 kV, 30 sec). The capillary was 
washed with 0.2 M NaOH for 2 min, and running buffer for 2 min before each injection. Data 
collection and corrected peak area analysis were performed by 32 Karat software obtained from 
Beckman coulter (Fullerton, CA, USA). Further data analysis were carried out by software 
Graph Pad Prism 4 (Graph Pad Software, Inc. California) and Excel.  
 
  Capillary conditioning method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 15:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 15:00 min BI:C1 BO:B1 Forward 
0:00 Separate – voltage 15 kV 60:00 min BI:A1 BO:A1 0.5 min ramp 
Reverse polarity 
60:00 End      
  Sample analyzing method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 2:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 2:00 min BI:C1 BO:B1 Forward 
 Inject – voltage 10 kV 30 sec SI:A1 BO:A1 override, Reverse 
polarity 
0:00 Separate – voltage 15 kV 12:00 min BI:A1 BO:A1 0.5 min ramp 
Reverse polarity 
1:00 Auto zero      
12:00 End      
BI: A1 – Separation buffer (Separation); BI: B1 – NaOH (Rinse); BI: C1 – Separation buffer 
(Rinse); BO: A1 – Separation buffer (Separation); BO: B1 – Waste 
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6.4.2 Assay description 
6.4.2.1     Buffer preparation 
Running buffer (75 mM phosphate buffer, 0.002% polybrene, pH 5.6) was prepared as below: 
 3.34 g Na2HPO4·2H2O (177.99 g/mol) and 500 µl 1% polybrene ( 30 mg polybrene + 3 ml water) 
were added to 250 ml water, pH value was adjusted by phosphoric acid from pH 9.2 to pH 5.6, 
then to use ultrasonic bath for 5 min. The CE current should be around -80 µA by using this 
buffer (with separate voltage -15kV).  
BGE buffer is 5 mM phosphate buffer, 0.0001% polybrene, pH 7.4. 3.34 g Na2HPO4·2H2O 
(177.99 g/mol) and 500 µl 1% polybrene ( 30 mg polybrene + 3 ml water) were added to 250 ml 
water, pH value was adjusted by phosphoric acid from pH 9.2 to pH 7.4, then further 1 to 15 
dilute with water. 
The enzyme reaction buffer contained 10 mM HEPES, 16 mM MgCl2. Buffer pH values was pH 
7.1, which was adjusted at 37°C with NaOH. We found out that the detection is much better 
when we used HEPES buffer instead of Tris buffer. The detection difference is shown below 
(The analytes are: PAP 1 µM, AMP 5 µM): 
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6.4.2.2     Pipetting scheme 
 
Inhibitor screening Substrate screening Kinetic testing Inhibition testing 
10 µl Triton X-100 
1% 
10 µl substrate 500 
µM 
10 µl inhibitor 500 
µM (lipid) 
 
Evaparate 
methanol/chloroform 
from above mixture 
 
25 µl PAPS (60 µM) 
 
5 µl water or 
inhibitor (non-lipid) 
 
20 µl CST in buffer 
(25 mM HEPES, 40 
mM MgCl2) 
37°C, 30 min 
60°C, 10 min 
10 µl Triton X-100 
1% 
10 µl substrate 500 
µM 
 
 
 
Evaparate 
methanol/chloroform 
from above mixture 
 
25 µl PAPS (60 µM) 
 
5 µl water 
 
 
20 µl CST in buffer 
(25 mM HEPES, 40 
mM MgCl2) 
37°C, 30 min 
60°C, 10 min 
10 µl Triton X-100 
1% 
10 µl substrate 
(different 
concentrations) 
 
 
Evaparate 
methanol/chloroform 
from above mixture 
 
25 µl PAPS 
 
5 µl water 
 
 
20 µl CST in buffer 
(25 mM HEPES, 40 
mM MgCl2) 
37°C, 30 min 
60°C, 10 min 
10 µl Triton X-100 
1% 
10 µl substrate 500 
µM 
Required amount of 
inhibitor (lipid) 
 
Evaparate 
methanol/chloroform 
from above mixture 
 
25 µl PAPS (60 µM) 
 
5 µl water or 
inhibitor (non-lipid) 
 
20 µl CST in buffer 
(25 mM HEPES, 40 
mM MgCl2) 
37°C, 30 min 
60°C, 10 min 
 
Dilution scheme for substrate and PAPS 
substrate 
curve 
(f.c. µM) 
 
 
con.* volume 
 
 
solvent = 1:1 methanol/chloroform 
400 2000 µM * 10 µl   
300 1500 µM * 10 µl 1500 µM = 30 µl 2000 µM + solvent 10 µl 
200 1000 µM * 10 µl 1000 µM = 20 µl 1500 µM + solvent 10 µl 
100 500 µM * 10 µl 500 µM = 15 µl 1000 µM + solvent 15 µl 
50 250 µM * 10 µl 250 µM = 15 µl 500 µM + solvent 15 µl 
25 125 µM * 10 µl 125 µM = 15 µl 250 µM + solvent 15 µl 
12.5 62.5 µM * 10 µl 62.5 µM = 15 µl 125 µM + solvent 15 µl 
6.25 36.25 µM * 10 µl 36.25 µM = 15 µl 62.5 µM + solvent 15 µl 
PAPS in 
substrate 
curve for 
(f.c. µM) 
 
 
 
need con (µM) 
  
400 800 800 µM = 80 µl 850 µM + water 5 µl 
300 600 600 µM = 60 µl 800 µM + water 20 µl 
200 400 400 µM = 40 µl 600 µM + water 20 µl 
100 200 200 µM = 30 µl 400 µM + water 30 µl 
50 100 100 µM = 30 µl 200 µM + water 30 µl 
25 50 50 µM = 30 µl 100 µM + water 30 µl 
12.5 25 25 µM = 30 µl 50 µM + water 30 µl 
6.25 12.5 12.5 µM = 30 µl 25 µM + water 30 µl 
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inhibition 
curve 
(f.c. µM) 
 
 
con.* volume 
 
 
solvent = 1:1 methanol/chloroform 
2000 2 mM * 50 µl   
1000 2 mM * 25 µl   
500 2 mM * 12.5 µl   
250 1250 µM * 10 µl 1250 µM = 25 µl 2 mM + solvent 15 µl 
100 500 µM * 10 µl 500 µM = 10 µl 1250 µM + solvent 15 µl 
30 150 µM * 10 µl 150 µM = 10 µl 500 µM + solvent 23 µl 
10 50 µM * 10 µl 50 µM = 10 µl 150 µM + solvent 20 µl 
 
6.4.2.3     Calibration and validation 
The test mixture was prepared with 50 µl CST reaction sample and 50 µl internal standard (I.S.) 
GDP 20 µM. This mixture was further 1:4 diluted in buffer 5 mM phosphate with 0.0001% 
polybrene at pH 7.4. Then 90 µl diluted mixture was pipetted to the CE sample vial and 
subsequently measured by CE. The linearity of the quantitative determination, the limits of 
detection (LOD) and the limits of quantification (LOQ) of the enzymatic product adenosine-3′,5′-
diphosphate (PAP) were determined by processing five-point calibration curves (triplicate 
samples with duplicate measurements) in the presence of 2.5 µM GDP as I.S. The precision and 
accuracy values were determined at the following concentrations (triplicate samples with 
duplicate measurements): 1.25, 0.625, 0.25, 0.125 and 0.0625 µM, in the presence of 2.5 µM 
GDP as I.S. Accuracy was determined by calculating the ratios of the predicted concentrations 
and the spiked values, and relative standard deviations were calculated. 
6.4.2.4     Enzyme catalytic reaction 
We carried out the CST catalytic reaction in a total volume of 50 µl, containing 3'-
phosphoadenosine-5'-phosphosulfate and cerebrosides (concentrations of 3'-phosphoadenosine-
5'-phosphosulfate and cerebrosides varied according to assay type) in 10 mM HEPES, 16 mM 
MgCl2, 0.2% (v/v) Triton X-100, pH 7.1 reaction buffer. All Lipids and Triton X-100 were 
prepared in chloroform/methanol (1:1), we pipetted lipids and Triton X-100 to reaction vials, and 
let chloroform/methanol dry before adding reaction buffer. Reactions were initiated by the 
addition of 938 ng human cerebroside sulfotransferase (CST), and then incubated at 37 °C for 30 
min. All enzymatic reactions were stopped by heating (10 min, 60 °C).  
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Reactions were initiated by the addition of CST. The reaction vials were incubated at 37°C for 
30 min. All enzymatic reactions were quenched by heating (10 min, 60°C). 
Determination of kinetic parameters for CST. For the determination of the kinetic parameters 
(Km and Vmax), 8 different substrate concentrations were chosen. Negative controls were 
performed in the presence of heat-inactivated enzyme (10 min, 60 °C). Each analysis was 
repeated three times in independent experiments.  
Investigation of CST inhibitors. For CST inhibitor characterization, full concentration-inhibition 
curves were determined by testing a suitable range of inhibitor concentrations, and then IC50 
value was calculated. The substrate (cerebrosides) concentration was 100 µM, and substrate 
conversion was strictly controlled to be below 15%. Negative controls were performed in the 
presence of heat-inactivated enzyme (10 min, 60 °C). Each analysis was repeated three times in 
independent experiments. For the determination of inhibition mechanism, 8 different substrate 
concentrations and 3 different inhibitor concentrations were used, and each analysis was carried 
out with duplicate measurements. 
 
6.4.3 Compound preparation and selection 
A group of analogs of cerebrosides were selected for substrate and inhibitor screening. 
Table 6.4. Screening test with cerebroside analogs 
  
Name 
 
Structure 
β lipids 
 α lipids 
 
Stock 
conc. 
(mM) 
Substrate 
screening 
(activity% 
at 100 µM) 
 
Inhibitor 
screening 
on 
cerebrosides
* 
(inhi% at 
100 µM) 
Inhibitor 
screening on 
KRN7000 
(inhi% at 100 
µM) 
 β lipids      
 
1 
 
 
glucocere
brosides 
 
2 
 
19% 
 
9% 
 
-5% 
 
2 
β- 
KRN7000 
O
OH
O
OH
HO OH
C13H27
HN
OH
O C25H51
OH
 
0.25 
 
42% 
 
38% 
 
-42% 
 α lipids      
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3 
 
JG185 
(C2) 
 
 
10 
 
40% 
 
-12% 
 
-1% 
 
 
4 
 
JG186 
(C5) O
OH
O
OH
HO OH
C13H27
HN
OH
O C4H9
OH
 
10 
 
30% 
 
-18% 
 
-4% 
 
5 
 
 
PBS25 
(C8) 
 
2 
 
22% 
 
- 
 
- 
 
6 
 
JG189 
(C11) 
 
8 
 
32% 
 
-43% 
 
1% 
 
7 
 
JG195 
(C14) O
OH
O
OH
HO OH
C13H27
HN
OH
O C13H27
OH
 
1 
 
21% 
 
-38% 
 
-24% 
 
8 
 
C16 
O
OH
O
OH
HO OH
C13H27
HN
OH
O C15H31
OH
 
2 
 
9% 
 
12% 
 
14% 
 
9 
 
JG187 
(C19) 
 
1 
 
25% 
 
-50% 
 
4% 
 
10 
 
JG190 
(C26) 
 
 
1 
 
51% 
 
3% 
 
- 
 
11 
 
JG188 
 
8 
 
32% 
 
-26% 
 
5% 
 
 
12 
 
 
NP230 
O
OH
O
HO OH
C13H27
HN
OH
O C25H51
OH
HN O
Cl
Cl
 
 
1 
 
 
15% 
 
 
4% 
 
 
1% 
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13 
JG198  
6 
 
16% 
 
4% 
 
-30% 
 
14 
JG201  
1 
 
19% 
 
-7% 
 
1% 
*Cerebroside was obtained from Matreya LLC (Pleasant Gap, PA, USA); according to the 
supplier it consists of a mixture of saturated or unsaturated alkyls (C16:0, C18:0, C20:0, C22:0, 
C23:0, C24:0-C27, C24:1-C27:1) or hydroxyalkyls (C18:0(2-OH), C20:0(2-OH), C22:0(2-
OH),C23:0(2-OH), C24:0(2-OH), C24:1(2-OH), C25:1(2-OH)). 
 
 
 
6.5 Analysis of the staphylococcus aureus capsule biosynthesis pathway  
6.5.1 Capillary electrophoresis set up 
All experiments were carried out by using a P/ACE MDQ capillary electrophoresis system 
(Beckman Instruments, Fullerton, CA, USA) equipped with a DAD detection system. Data 
collection and corrected peak area analysis were performed by 32 Karat software obtained from 
Beckman coulter (Fullerton, CA, USA). The capillary temperature was kept constant at 15°C. 
The electrophoretic separations were carried out by using fused-silica capillary of 60 cm total 
length (50 cm effective length) × 75.5 µm (id) ×363.7 µm (od) obtained from Polymicro 
Technologies (Kehl, Germany) obtained from Optronis GmbH]. The following conditions were 
applied: λmax = 260 nm, separation voltage = -15 kV, running buffer 68 mM CAPS buffer 
containing polybrene 0.002%, pH 12.4 (adjusted by NaOH), electrokinetic injection (-1 kV, 
20sec). The capillary was washed with 0.2 N NaOH aq. for 2 min (20 psi) and with running 
buffer 3 min (20 psi) before each injection.  The test mixture was prepared with 50 µl sample 
dilution and 50 µl internal standard (I.S.). Sample dilution was 1:40 diluted enzyme reaction 
mixture in autoclaved Millipore water. The internal standard was 6.25 µM PAP dissolved in 
autoclaved Millipore water. 90 µl test mixture was pipetted to the sample vial and subsequently 
measured by CE. Further data analysis were carried out by software Graph Pad Prism 4 (Graph 
Pad Software, Inc. California) and Excel.  
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  Capillary conditioning method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 10:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 10:00 min BI:C1 BO:B1 Forward 
0:00 Separate – voltage 5 kV 60:00 min BI:A1 BO:A1 0.5 min ramp 
Reverse polarity 
60:00 End      
  Sample analyzing method   
Time 
(min) 
Event Value Duration Inlet 
vial 
Outlet 
vial 
Summary 
 Rinse – pressure 20 psi 2:00 min BI:B1 BO:B1 Forward 
 Rinse – pressure 20 psi 3:00 min BI:C1 BO:B1 Forward 
 Inject – voltage 1 kV 20 sec SI:A1 BO:A1 override, Reverse 
polarity 
0:00 Separate – voltage 15 kV 10:00 min BI:A1 BO:A1 0.5 min ramp 
Reverse polarity 
1:00 Auto zero      
10:00 End      
BI: A1 – Separation buffer (Separation); BI: B1 – NaOH (Rinse); BI: C1 – Separation buffer 
(Rinse); BO: A1 – Separation buffer (Separation); BO: B1 – Waste 
 
 
6.5.2 Assay description 
6.5.2.1     Buffer preparation 
Running buffer (68 mM CAPS buffer, 0.002% polybrene, pH 12.4) was prepared as below: 
3.32g CAPS and 440 µL polybrene 1% were added to 200 ml Millipore water, pH value was 
adjusted by NaOH (20 ml NaOH 1 M) from pH 6.14 to pH 12.4, then to use ultrasonic bath for 5 
min.. The CE current should be around -85 µA by using this buffer (with separate voltage -15kV). 
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The enzyme reaction buffer contained 10 mM KPi, 10 mM MgCl2, pH 7.5. Assays for the 
synthesis of UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose, additionally included 0.8% 
(v/v) Triton x-100. For CapD assays, cofactors NADP was added in a concentration of 3 mM for 
kinetic testing and 600 µM for inhibition testing.  
 
6.5.2.2     Pipetting scheme 
The pipetting works were carried out by Hannah Ulm and Marvin Rausch. 
 
CapD kinetic  CapE kinetic 
 
15 µl UDP-GlcNAc (different 
concentrations)/H2O (control) 
 
10 µl CapD preparation 
 
10 µl TritonX-100 (4% (w/v)) 
 
10 µl NADP (10 mM) 
 
5 µl KPi (100 mM) 
 
ad 50 µl H2O 
 
 
  
15 µl UPD-GlcNAc (different 
concentrations)/H2O (control) 
 
5 µl CapE preparation 
 
0.5 µl MgCl2 (1 M) 
 
 
 
4.5 µl KPi (100 mM) 
 
ad 50 µl H2O 
 
CapD inhibition  CapE inhibition 
 
5 µl UDP-GlcNAc (10 mM) 
 
5 µl CapD preparation 
 
10 µl TritonX-100 (4% (w/v)) 
 
3 µl NADP (10 mM) 
 
5 µl KPi (100 mM) 
 
+ 5 µl inhibitor (different 
concentrations/DMSO (10% (w/v)) 
 
ad 50 µl H20 
 
  
5 µl UDP-GlcNAc (10 mM) 
 
5 µl CapE preparation 
 
0,5 µl MgCl2 (1M) 
 
 
 
5 µl KPi (100 mM) 
 
+ 5 µl inhibitor (different 
concentrations/DMSO (10% (w/v)) 
 
ad 50 µl H20 
 
CapD + CapA/B  CapE + CapA/B 
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30 µl UPD-GlcNAc (10 mM) 
 
10 µl CapD preparation 
 
1 µl MgCl2 (1 M) 
 
2 µl DTT (500 mM) 
 
1 µl ATP (100 mM) 
 
8.8 µl KPi buffer (100 mM) 
 
20 µl NADP (10 mM) 
 
4 µl TritonX100 (20 %) 
 
6 µl CapA + 6.5 µl CapB 
 
ad 100 µl H2O 
 
30 µl UPD-GlcNAc (10 mM) 
1 µl MgCl2 (1 M) 
5 µl CapE preparation 
 
 
 
2 µl DTT (50 mM) 
 
1 µl ATP (100 mM) 
 
8.8 µl KPi buffer (100 mM) 
 
 
 
 
 
6 µl CapA + 6.5 µl CapB 
 
ad 100 µl H2O 
 
 
 
 
6.5.2.3     Calibration and validation  
The CapD and CapE reaction products are UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose 
and UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose, respectively. Since both 
compounds are not commercially available, we utilized enzymatic products for CE calibration. 
Recombinant CapE and PglF are both capable of catalyzing 100% conversion of the substrate 
UDP-D-GlcNAc. However, the final product concentrations in the reaction mixtures are lower 
than the initial substrate concentrations, due to simultaneous hydrolysis of substrate and products 
yielding UDP. To determine the actual product concentrations in the samples, we quantified the 
degradation product UDP, subtracted the respective values from the initial substrate amount and 
considered the difference to represent the amount of UDP-2-acetamido-2,6-dideoxy-α-D-xylo-
hex-4-ulose and UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose, respectively. The 
amount of UDP was determined as follows: UDP was diluted with water to different 
concentrations; then 50 µl aliquots of the different UDP dilutions were mixed with 50 µl of the 
I.S. PAP, which was prepared in biological matrix (PglF reaction mixture diluted 1:40 with 
water). Since UDP is also formed during in vitro PglF assays, UDP calibration was performed 
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using biological matrix as a blank value. The calibration and validation of UDP is shown as 
below: Y = 14.04 x - 21.74 
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The UDP peaks in Pg1F product (1 to 80 dilution from the reaction mixture) and CapE product 
(1 to 320 dilution from the reaction mixture) have been chosen and calculated. According to the 
calculation, the concentration of UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-ulose and UDP-
2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose in the 100% substrate converted samples were 
2.438 mM and 1.702 mM, respectively: 
 
UDP concentration in Pg1F reaction mixture 1 to 320 dilution: 
x = (y + 21.74 ) / 14.04 = (10.294+21.74)/14.4=2.282 µM 
Pg1F pro. con. in reaction mixture: Pg1F pro. con. in vial *320 = 2.270 mM 
I.S. UDP Avg. 
UDP/IS 
Avg.UDP con. 
in vial 
Avg. Pg1F pro. con. in vial (37.5-
UDP con.) 
5353 
3008 
5635 
2820 
5424 
2677 
624 
362 
409 
197 
646 
319 
 
 
10.294 
 
 
2.282 µM 
 
 
7.093 µM 
UDP in CapE reaction mixture 1 to 320 dilution: 
x = (y + 21.74 ) / 14.04 = (34.817+21.74)/14.4=4.028 µM 
CapE pro. con. in reaction mixture: CapE pro. con. in vial *320 = 1.711 mM 
I.S. UDP Avg. 
UDP/IS 
Avg UDP con. 
in vial 
Avg. CapE pro con. in vial (9.375-
UDP con.) 
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2726,0 
1784,0 
1849,0 
800,0 
1109,0 
596,0 
994, 
617, 
635, 
271, 
435, 
247, 
 
 
34.817 
 
 
4.028 µM 
 
 
5.347 µM 
 
The linearity of the quantitative determination and the limits of detection (LOD) and 
quantification (LOQ) of the enzymatic products UDP-2-acetamido-2,6-dideoxy-α-D-xylo-hex-4-
ulose and UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose were determined by 
processing six-point calibration curves (triplicate samples with duplicate measurements) in the 
presence of 3.125 µM PAP as I.S. The precision and accuracy values were determined at the 
following concentrations (triplicate samples with duplicate measurements): 0.44, 0.89, 3.55 and 
7.09 µM for UDP-2-acetamido-2,6-dideoxy-α-D-xylo-4-hexulose; 0.67, 1.34, 2.67 and 5.35 µM 
for UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hex-4-ulose in the presence of 3.125 µM PAP as 
I.S. Accuracy was determined by calculating the ratios of the predicted concentrations and the 
spiked values, and relative standard deviations were calculated. 
 
6.5.2.4 Enzyme catalytic reaction 
Reactions were initiated by the addition of 3 µg CapD-His6 or 8.5 µg CapE-His6. The reaction 
vials were incubated at 30°C. All enzymatic reactions were quenched by heating (5 min, 90°C). 
Determination of kinetic parameters for CapD and CapE. To determine the linear range of the 
enzymatic reactions, formation of CapD and CapE enzymatic products was monitored over time 
(6 time points, 10 min to 6 h) at 30°C with a substrate (UDP-D-GlcNAc) concentration of 1 mM. 
For the determination of the kinetic parameters (Km and Vmax), 8 different substrate 
concentrations were chosen. For CapD assays, the cofactor NADP was added at a concentration 
of 2 mM. Each analysis was repeated three times in independent experiments.  
Investigation of CapD and CapE inhibitors. A library of selected compounds (73 compounds for 
CapD; 46 compounds for CapE) (see Table 6.5 and Table 6.6) was initially screened at high 
concentrations of 100 µM (for highly water-soluble compounds) or at 10 µM, respectively. 
Subsequently, full concentration-inhibition curves were determined for the most potent inhibitors, 
and IC50 values were calculated. The substrate (UDP-D-GlcNAc) concentration for CapD and 
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CapE inhibition testing was 1 mM, and substrate conversion was strictly controlled to be below 
10%. For CapD assays, the cofactor NADP was added at a concentration of 600 µM. The IC50 
values of inhibitors were obtained by testing a suitable range of inhibitor concentrations (8 data 
points spanning three orders of magnitude). The incubation time was chosen to be within the 
linear range (30 min to 1 h). Negative controls were performed in the presence of heat-
inactivated enzyme (10 min, 100°C). Each analysis was repeated three times in independent 
experiments. For the determination of the inhibition mechanism, 8 different substrate 
concentrations and 3 different inhibitor concentrations were used, and each analysis was carried 
out with duplicate measurements. 
In vitro synthesis of the soluble capsule precursor UDP-D-FucNAc—The PglF-His6 enzymatic 
product was used as substrate for reconstitution of CapN catalytic activity. For this purpose, PglF 
reactions were carried out overnight and quenched by heating (5 min, 95°C). CapN catalyzed 
synthesis of UDP-D-FucNAc was carried out in a total volume of 40 µl. CapN-His6 (12 µg) was 
incubated in the presence of ~3mM UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose, 0.8% 
(v/v) Triton X-100 and 10 mM KPi, pH 7.5, for 2 h at 30°C. Alternatively, synthesis of UDP-D-
FucNAc was performed in a one-pot-assay containing 3.5 µg PglF, 12 µg CapN, 3 mM UDP-
GlcNAc, 0.8% (v/v) Triton X-100 and 10 mM KPi, in a total volume of 60 µl. Cofactors NADH 
or NADPH were added in a concentration of 1.875 mM if indicated. All enzymatic reactions 
were quenched by heating (5 min, 90°C).  
 
6.5.2.5     The vivo study 
All in vivo assays were carried out by Xue Li.  
Quantitation of CP5 produced by cultures in the absence and presence of CapD inhibitor – An 
enzyme-linked immunosorbent inhibition assay (ELISA) method 144 was used to quantitate CP5 
expression by S. aureus cultivated in vitro. The assay is based on the ability of encapsulated 
bacteria (trypsinized to remove protein A) or purified CP5 to absorb capsular antibodies from 
immune serum. The method is sensitive to ~1 ng/ml CP5 and is useful for quantitating capsule 
production by different S. aureus strains or by the same strain grown under different conditions. 
Briefly, wells of a microtiter plate were coated with purified CP5 (4 µg/ml) coupled to poly-L-
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lysine by the cyanuric acid chloride method 145. After 18 h at 4°C, the microtiter plate was 
washed and blocked at 4°C overnight with 0.05% skimmed milk. The CP5+ S. aureus Reynolds 
strain 146 was cultivated overnight with aeration in 5 ml of Columbia broth containing ampicillin 
(0 – 270 µM). The bacteria were harvested, washed once in phosphate buffer, and then 
trypsinized (1 mg trypsin/ml of 0.1 M phosphate buffer, pH 8) for 60 min at 37°C. After washing, 
the bacterial suspensions were serially diluted threefold from ~3 x 108 to ~3 x 105 CFU/ml. The 
bacterial concentrations were verified by plating dilutions of the suspensions on tryptic soy agar 
plates. Polyclonal CP5-specific antiserum was diluted 1:20,000 and incubated overnight at 4°C 
with serial dilutions of the bacteria.  Samples were centrifuged, and the absorbed serum samples 
(supernatants) were added to the coated and blocked microtiter plate. Following a 2 h incubation 
with absorbed or nonabsorbed serum samples, the plates were washed with PBS/Tween, and 
alkaline phosphatase-conjugated protein A/G (Thermo Scientific; 1:3000) was added to each 
well. After 2 hours at ambient temperature, the plate was again washed, and the substrate p-
nitrophenyl phosphate was added. When the wells containing unabsorbed serum samples reached 
an OD405 nm of ~2.0, the plate was read on a Bio-TEK Power Wave HT ELISA reader. The 
concentration of each sample (CFU/ml) that resulted in 50% inhibition of antibody binding (IC50) 
was determined, and the IC50 of cultures containing ampicillin were compared to that of cultures 
without ampicillin.  
 
6.5.3 Compound preparation and selection 
A library of selected compounds (73 compounds for CapD; 46 compounds for CapE) was 
initially screened. The structures and screening results were shown in Table 6.5 and Table 6.6. 
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Table 6.5. CapD screening results*     
 
  
 
 
 
Compound (code) name 
 
 
 
 
Structure 
% inhibition 
of enzyme 
activity at 
test 
concentration 
given in 
brackets 
UDP/UTP derivatives 
 
1 
 
Ali 179a 
 
1% 
(100 µM) 
 
2 
 
Ali 412Ca 
O
P
O
OH
HO
P
O
OH
Cl
Cl
O
O
HO
O N NH
OH
O
P
O
OH
 
6% 
(100 µM) 
 
3 
 
Ali 404Ba 
 
7% 
(100 µM) 
 
4 
 
Ali 411Aa 
 
15% 
(100 µM) 
 
5 
 
Ali 409Aa 
 
4% 
(100 µM) 
 
6 
 
Ali 149a 
 
-18% 
(100 µM) 
 
7 
 
Ali 452a 
 
-4% 
(100 µM) 
 
46 
 
UDP-glucosea 
 
13% 
(100 µM) 
 
9 
 
UDPa 
 
15% 
(100 µM) 
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10 
 
UTPa 
 
-4% 
(100 µM) 
anthraquinone derivatives 
 
11 
 
YB001a 
O
O
NH2
SO3Na
HN NH2
SO3Na
 
10% 
(10 µM) 
 
12 
 
YB003a 
O
O
NH2
SO3Na
HN NH2
CO2H
 
2% 
(10 µM) 
 
13 
 
YB005a 
 
0% 
(10 µM) 
 
14 
 
YB009a 
 
25% 
(10 µM) 
 
15 
 
YB010b 
 
17% 
(10 µM) 
 
16 
 
YB011a 
 
25% 
(10 µM) 
 
17 
 
YB012a 
O
O
NH2
SO3Na
HN OMe
 
26% 
(10 µM) 
 
18 
 
YB013a 
 
24% 
(10 µM) 
 
19 
 
YB014a 
 
21% 
(10 µM) 
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20 
 
YB015a 
 
10% 
(10 µM) 
 
21 
 
YB016b 
 
-1% 
(10 µM) 
 
22 
 
YB017b 
 
14% 
(10 µM) 
 
23 
 
YB019a 
 
11% 
(10 µM) 
 
24 
 
YB020b 
O
O
NH2
SO3Na
HN
NH2
 
34% 
(10 µM) 
 
25 
 
YB024a 
O
O
NH2
SO3Na
HN
CH3
CH3
H3C
NH2
SO3Na
 
13% 
(10 µM) 
 
26 
 
YB028b 
 
29% 
(10 µM) 
 
27 
 
YB029a 
 
13% 
(10 µM) 
 
28 
 
YB031a 
O
O
NH2
SO3Na
HN
P
O
OEt
OEt
 
-4% 
(10 µM) 
 
29 
 
YB032b 
O
O
NH2
SO3Na
HN
 
25% 
(10 µM) 
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30 
 
YB035b 
O
O
NH2
SO3Na
HN
 
32% 
(10 µM) 
 
31 
 
YB038a 
 
23% 
(10 µM) 
 
32 
 
YB042b 
 
0% 
(10 µM) 
 
33 
 
YB047a 
O
O
NH2
SO3Na
HN
N
H
O
 
20% 
(10 µM) 
 
34 
 
YB053b 
O
O
NH2
SO3Na
HN
CO2H
F
 
33% 
(10 µM) 
 
35 
 
YB055a 
O
O
NH2
SO3Na
HN
SO3Na
 
-10% 
(10 µM) 
 
36 
 
YB056b 
O
O
NH2
SO3Na
HN
SO3Na
 
27% 
(10 µM) 
 
37 
 
YB057b 
O
O
NH2
SO3Na
HN
NaO3S
 
 
32% 
(10 µM) 
 
38 
 
YB058b 
 
25% 
(10 µM) 
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39 
 
YB068b 
 
17% 
(10 µM) 
 
40 
 
YB083b 
O
O
NH2
SO3Na
HN
S
 
35% 
(10 µM) 
 
41 
 
YB086b 
O
O
NH2
SO3Na
HN
 
25% 
(10 µM) 
 
42 
 
YB087b 
 
32% 
(10 µM) 
 
 
 
43 
 
 
 
RB2a 
 
17% 
(10 µM) 
antibiotics 
 
 
44 
 
 
ampicillinb 
 
41% 
(10 µM) 
 
 
45 
 
 
dicloxacillinb 
 
44% 
(10 µM) 
 
 
47 
            
 
 
           amoxicillinb 
 
                         
 
-3% 
(10 µM) 
 
 
48 
 
 
cefiximeb 
 
3% 
(10 µM) 
 
 
49 
 
 
cefotaxime sodiumb 
 
5% 
(10 µM) 
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50 
 
 
 
phenoxymethylpenicillinic 
acidb 
 
-8% 
(10 µM) 
 
 
 
51 
 
 
 
benzathine 
benzylpenicillinb 
 
-3% 
(10 µM) 
 
 
52 
 
 
flucloxacillin sodiumb 
 
-5% 
(10 µM) 
 
 
53 
 
 
piperacillinb 
 
-4% 
(10 µM) 
 
54 
 
pivampicillinb 
(prodrug) 
 
-1% 
(10 µM) 
 
 
55 
 
 
sultamicillinb 
(prodrug) 
 
-6% 
(10 µM) 
 
 
56 
 
 
sultamicillin tosylateb 
(prodrug) 
 
 
1% 
(10 µM) 
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57 
 
 
ticarcillin monosodiumb 
 
-8% 
(10 µM) 
 
 
58 
 
 
bacampicillin 
hydrochlorideb 
(prodrug) 
 
       
     4% 
   (10 µM) 
 
 
59 
 
 
cloxacillin sodiumb 
 
0% 
(10 µM) 
 
 
60 
 
 
penicillin G sodium saltb  
 
-33% 
(10 µM) 
 
 
61 
 
 
mecillinamb  
 
-6% 
(10 µM) 
 
 
 
63 
 
 
 
aztreonamb 
 
 
-11% 
(10 µM) 
 
 
64 
 
 
cefuroxim sodium saltb 
 
 
-12% 
(10 µM) 
 
65 
 
ceftaroline fosamilb 
 
 
9% 
(10 µM) 
 
 
158 
 
 
68 
 
 
oxacillin sodiumb 
 
 
16% 
(10 µM) 
 
 
69 
 
 
ertapenem sodium saltb 
 
 
1% 
(10 µM) 
 
 
70 
 
 
meropenem trihydrateb 
N
O
OH
S
H
O
CH3
H3C
OH
H
N
O
N CH3
CH3H
3H2O  
 
-26% 
(10 µM) 
 
 
73 
 
 
potassium clavulanateb 
N
O
H
CO2K
O
OH
 
 
 
 
 
-23% 
(100 µM) 
biological interesting compounds 
 
 
 
62 
 
 
pentapetidea  
(L-Ala-D-Glu-gamma-L-
Lys-D-Ala-D-Ala) 
 
 
51% 
(100 µM) 
 
 
 
66 
 
 
UDP-D-MurNAc-
pentapeptidea 
 
 
 
14% 
(100 µM) 
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67 
 
 
lipid IIa 
 
 
 
 
 
67% 
(100 µM) 
 
71 
 
 
D-Ala-D-Alaa 
 
26% 
(100 µM) 
 
 
72 
 
 
N-, N-ε-Diacetyl-Lys-D-
Ala-D-Alaa 
 
 
 
28% 
(100 µM) 
Other compounds 
 
 
8 
 
 
suraminb 
 
 
-14% 
(10 µM) 
*Compounds were screened at 10 µM or 100 µM depending on their water-solubility. Percent 
inhibition at the screening concentration is provided. In case of negative values the compounds 
activated enzymatic activity. For potent inhibitors, full concentration-inhibition curves were 
recorded and IC50 values were determined. Final concentration of the substrate UDP-D-GlcNAc 
was 1 mM in all screening tests. 
aCompounds were screened in buffer without DMSO. 
bCompounds were screened in buffer with 1% DMSO. 
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Table 6.6. CapE screening results*   
 
 Compound 
(code) name 
Structure % inhibition of 
enzyme activity 
at test 
concentration 
given in brackets 
UDP/UTP deriatives 
 
1 
 
Ali 179a 
 
33% 
(100 µM) 
 
2 
 
Ali 412Ca 
 
27% 
(100 µM) 
 
3 
 
Ali 404Ba 
 
33% 
(100 µM) 
 
4 
 
Ali 411Aa 
 
35% 
(100 µM) 
 
5 
 
Ali 409Aa 
 
22% 
(100 µM) 
 
6 
 
Ali 149a 
 
18% 
(100 µM) 
 
7 
 
Ali 452a 
 
25% 
(100 µM) 
 
46 
 
UDP-
glucosea 
 
17% 
(100 µM) 
 
9 
 
UDPa 
 
22% 
(100 µM) 
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10 
 
UTPa 
N
OO
O
HO OH
H
N
O
P
O
P
O
P
HO
O O
OH
O
OHOH
 
 
 
20% 
(100 µM) 
anthraquinone compounds 
 
11 
 
YB001a 
O
O
NH2
SO3Na
HN NH2
SO3Na
 
17% 
(10 µM) 
 
12 
 
YB003a 
O
O
NH2
SO3Na
HN NH2
CO2H
 
18% 
(10 µM) 
 
13 
 
YB005a 
 
21% 
(10 µM) 
 
14 
 
YB009a 
 
15% 
(10 µM) 
 
15 
 
YB010b 
 
21% 
(10 µM) 
 
16 
 
YB011a 
 
7% 
(10 µM) 
 
17 
 
YB012a 
 
12% 
(10 µM) 
 
18 
 
YB013a 
 
9% 
(10 µM) 
 
19 
 
YB014a 
 
5% 
(10 µM) 
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20 
 
YB015a 
 
7% 
(10 µM) 
 
21 
 
YB016b 
 
7% 
(10 µM) 
 
22 
 
YB017b 
 
-1% 
(10 µM) 
 
23 
 
YB019a 
 
9% 
(10 µM) 
 
24 
 
YB020b 
O
O
NH2
SO3Na
HN
NH2
 
15% 
(10 µM) 
 
25 
 
YB024a 
O
O
NH2
SO3Na
HN
CH3
CH3
H3C
NH2
SO3Na
 
9% 
(10 µM) 
 
26 
 
YB028b 
 
19% 
(10 µM) 
 
27 
 
YB029a 
 
13% 
(10 µM) 
 
28 
 
YB031a 
O
O
NH2
SO3Na
HN
P
O
OEt
OEt
 
5% 
(10 µM) 
 
29 
 
YB032b 
O
O
NH2
SO3Na
HN
 
18% 
(10 µM) 
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30 
 
YB035b 
O
O
NH2
SO3Na
HN
 
18% 
(10 µM) 
 
 
31 
 
 
YB038a 
 
15% 
(10 µM) 
 
 
32 
 
 
YB042b 
 
12% 
(10 µM) 
 
 
33 
 
 
YB047a 
O
O
NH2
SO3Na
HN
N
H
O
 
8% 
(10 µM) 
 
 
34 
 
 
YB053b 
O
O
NH2
SO3Na
HN
CO2H
F
 
7% 
(10 µM) 
 
 
35 
 
 
YB055a 
O
O
NH2
SO3Na
HN
SO3Na
 
-1% 
(10 µM) 
 
 
36 
 
 
YB056b 
O
O
NH2
SO3Na
HN
SO3Na
 
4% 
(10 µM) 
 
 
37 
 
 
YB057b 
O
O
NH2
SO3Na
HN
NaO3S
 
 
13% 
(10 µM) 
 
 
38 
 
 
YB058b 
 
0% 
(10 µM) 
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39 
 
YB068b 
 
12% 
(10 µM) 
 
40 
 
YB083b 
O
O
NH2
SO3Na
HN
S
 
6% 
(10 µM) 
 
41 
 
YB086b 
O
O
NH2
SO3Na
HN
 
9% 
(10 µM) 
 
42 
 
YB087b 
 
17% 
(10 µM) 
 
 
43 
 
 
RB2a 
 
15% 
(10 µM) 
antibiotics 
 
44 
 
ampicillinb 
 
5% 
(10 µM) 
 
45 
 
dicloxacillinb 
 
6% 
(10 µM) 
Other compounds 
 
 
8 
 
 
suraminb 
 
75% 
(10 µM) 
*Compounds were screened at 10 µM or 100 µM depending on their water-solubility. Percent 
inhibition at the screening concentration is provided. In case of negative values the compounds 
activated enzymatic activity. For potent inhibitors, full concentration-inhibition curves were 
recorded and IC50 values were determined. Final concentration of the substrate UDP-D-GlcNAc 
was 1 mM in all screening tests. 
aCompounds were screened in buffer without DMSO. 
bCompounds were screened in buffer with 1% DMSO. 
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7 Abbreviations 
ad up to (Latin)   
Ado adenosine 
ADP adenosine-5’-diphosphate   
AP alkaline phosphatases  
ATP adenosine-5’-triphosphate   
AU absorbance units 
BGE background electrolyte  
BSA bovine serum albumin   
C. jejuni Campylobacter jejun 
C55P bactoprenol 
CAPS 3-(cyclohexylamino)-1-propanesulfonic acid 
CE capillary electrophoresis 
CFU colony forming units 
CHO Chinese hamster ovary   
Ci Curie   
CNS central nervous system   
con  concentration 
conc. concentration 
CP capsular polysaccharide 
CP5 serotype 5 capsular polysaccharide 
CP8 serotype 8 capsular polysaccharide 
cpm counts per minute   
CST cerebroside sulfotransferase  
Da Dalton   
DAD diode array detector 
DDM n-dodecyl-β-D-maltoside 
D-FucNac D-N-acetylfucosamine 
D-ManNAcA D-N-acetylmannosaminuronic acid 
DMSO dimethyl sulfoxide   
E. coli Escherichia coli 
e.g. exempli gratia (for example)   
eN ecto-5’-nucleotidase 
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E-NPP ectonucleotide pyrophosphatase/phosphodiesterase family 
E-NTPDase ectonucleoside triphosphate diphosphohydrolase  
EOF electroosmotic flow 
et al. et alii (and others)   
f.c. final concentration   
FASS field amplifying sample stacking 
FDA US Food and Drug Administration 
FS fused-silica 
g gram   
GPI glycosylphosphatidylinositol 
h hour(s)   
His6-tag hexahistidine-tag 
HTS high throughput screening 
I.S. internal standard 
IC50  half maximal inhibitory concentration 
ICH 
International Conference on Harmonisation  
(of Technical Requirements for Registration of Pharmaceuticals for Human Use) 
IMAC IMAC, immobilized metal ion affinity chromatography 
Ino inosine 
IPTG isopropyl-β-D-1-thiogalactopyranoside 
KD  equilibrium dissociation constant 
Ki equilibrium inhibition constant 
Kpi potassium phosphate buffer 
l liter 
LB lysogeny broth 
L-FucNac L-N-acetylfucosamine 
LIF laser-induced fluorescence  
lipid II 
undecaprenyl-pyrophosphoryl-N-acetylmuramyl-(pentapeptide)-N- 
acetylglucosamine 
LOD limit of detection 
LOQ limit of quantification 
m  meter 
M  Molar 
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MEKC micellar electrokinetic chromatography 
MeOH methanol 
min  minute(s) 
MLD metachromatic leukodystrophy 
MRSA Methicillin-resistant Staphylococcus aureus 
MS mass spectroscopy 
MurNAc D-N-acetylmuraminic acid 
n number of experiments   
n/a not available   
NAD nicotinamide adenine dicucleotide 
NADH nicotinamide adenine dicucleotide 
NADP nicotinamide adenine dicucleotide phosphate 
NADPH nicotinamide adenine dicucleotide phosphate 
NaPi sodium phosphate buffer 
nd no data   
NEB New England Biolabs 
Ni-NTA nickel-nitrilotriacetic acid 
PAP adenosine-3′,5′-diphosphate sodium salt 
PAPS 3′-phosphoadenosine-5′-phosphosulfate  
PB polybrene (hexadimethrine bromide) 
PBP Penicillin-binding protein 
PG peptidoglycan 
POMs polyoxometalates 
rpm rounds per minute   
RSD relative standard deviation 
rt room temperature   
s second(s)   
S. aureus Staphylococcus aureus 
S. pneumoniae Streptococcus pneumoniae 
SDR short-chain dehydrogenase/reductase 
SEM  standard error of the mean 
Tris tris(hydroxymethyl)aminomethane   
U units   
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UDP-D-FucNAc UDP-D-N-acetylfucosamine 
UDP-D-GlcNAc UDP-D-N-acetylglucosamine 
UDP-D-ManNAcA UDP-D-N-acetylmannosaminuronic acid 
UDP-D-MurNAc-
pentapeptide 
UDP-D-N-acetylmuramyl-pentapeptide 
UDP-L-FucNAc UDP-L-N-acetylfucosamine 
UV ultraviolet   
V volume   
VDW the van der Waals force  
vs. versus   
wt wild-type   
WTA wall teichoic acid 
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